{
"instance": {
"abbv-20220630.htm": {
"axisCustom": 1,
"axisStandard": 32,
"contextCount": 644,
"dts": {
"calculationLink": {
"local": [
"abbv-20220630_cal.xml"
]
},
"definitionLink": {
"local": [
"abbv-20220630_def.xml"
]
},
"inline": {
"local": [
"abbv-20220630.htm"
]
},
"labelLink": {
"local": [
"abbv-20220630_lab.xml"
]
},
"presentationLink": {
"local": [
"abbv-20220630_pre.xml"
]
},
"schema": {
"local": [
"abbv-20220630.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
"https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
"https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
"https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
"https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
"https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
"https://xbrl.sec.gov/country/2021/country-2021.xsd",
"https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
"https://xbrl.sec.gov/exch/2021/exch-2021.xsd"
]
}
},
"elementCount": 561,
"entityCount": 1,
"hidden": {
"http://fasb.org/us-gaap/2021-01-31": 1,
"http://xbrl.sec.gov/dei/2021": 5,
"total": 6
},
"keyCustom": 25,
"keyStandard": 259,
"memberCustom": 64,
"memberStandard": 62,
"nsprefix": "abbv",
"nsuri": "http://www.abbvie.com/20220630",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "0001001 - Document - Document and Entity Information",
"role": "http://www.abbvie.com/role/DocumentandEntityInformation",
"shortName": "Document and Entity Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2103102 - Disclosure - Supplemental Financial Information",
"role": "http://www.abbvie.com/role/SupplementalFinancialInformation",
"shortName": "Supplemental Financial Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2106103 - Disclosure - Earnings Per Share",
"role": "http://www.abbvie.com/role/EarningsPerShare",
"shortName": "Earnings Per Share",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "abbv:AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2109104 - Disclosure - Licensing, Acquisitions and Other Arrangements",
"role": "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements",
"shortName": "Licensing, Acquisitions and Other Arrangements",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "abbv:AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2111105 - Disclosure - Collaborations",
"role": "http://www.abbvie.com/role/Collaborations",
"shortName": "Collaborations",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2114106 - Disclosure - Goodwill and Intangible Assets",
"role": "http://www.abbvie.com/role/GoodwillandIntangibleAssets",
"shortName": "Goodwill and Intangible Assets",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2118107 - Disclosure - Integration and Restructuring Plans",
"role": "http://www.abbvie.com/role/IntegrationandRestructuringPlans",
"shortName": "Integration and Restructuring Plans",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DerivativesAndFairValueTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2121108 - Disclosure - Financial Instruments and Fair Value Measures",
"role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures",
"shortName": "Financial Instruments and Fair Value Measures",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DerivativesAndFairValueTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2131109 - Disclosure - Post-Employment Benefits",
"role": "http://www.abbvie.com/role/PostEmploymentBenefits",
"shortName": "Post-Employment Benefits",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:PostemploymentBenefitsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2134110 - Disclosure - Equity",
"role": "http://www.abbvie.com/role/Equity",
"shortName": "Equity",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2143111 - Disclosure - Income Taxes",
"role": "http://www.abbvie.com/role/IncomeTaxes",
"shortName": "Income Taxes",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:Revenues",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1001002 - Statement - Condensed Consolidated Statements of Earnings (Unaudited)",
"role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
"shortName": "Condensed Consolidated Statements of Earnings (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "-6",
"lang": "en-US",
"name": "us-gaap:SellingGeneralAndAdministrativeExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LegalMattersAndContingenciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2145112 - Disclosure - Legal Proceedings and Contingencies",
"role": "http://www.abbvie.com/role/LegalProceedingsandContingencies",
"shortName": "Legal Proceedings and Contingencies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LegalMattersAndContingenciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SegmentReportingDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2147113 - Disclosure - Segment Information",
"role": "http://www.abbvie.com/role/SegmentInformation",
"shortName": "Segment Information",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SegmentReportingDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2304301 - Disclosure - Supplemental Financial Information (Tables)",
"role": "http://www.abbvie.com/role/SupplementalFinancialInformationTables",
"shortName": "Supplemental Financial Information (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2307302 - Disclosure - Earnings Per Share (Tables)",
"role": "http://www.abbvie.com/role/EarningsPerShareTables",
"shortName": "Earnings Per Share (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R24": {
"firstAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i3c398cf1bbb44e6cab05bdbd1112685b_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2312303 - Disclosure - Collaborations (Tables)",
"role": "http://www.abbvie.com/role/CollaborationsTables",
"shortName": "Collaborations (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i3c398cf1bbb44e6cab05bdbd1112685b_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R25": {
"firstAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfGoodwillTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2315304 - Disclosure - Goodwill and Intangible Assets (Tables)",
"role": "http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables",
"shortName": "Goodwill and Intangible Assets (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfGoodwillTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i29cdb7db69bf450eb7b02443128fd82a_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2319305 - Disclosure - Integration and Restructuring Plans (Tables)",
"role": "http://www.abbvie.com/role/IntegrationandRestructuringPlansTables",
"shortName": "Integration and Restructuring Plans (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i29cdb7db69bf450eb7b02443128fd82a_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R27": {
"firstAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2322306 - Disclosure - Financial Instruments and Fair Value Measures (Tables)",
"role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables",
"shortName": "Financial Instruments and Fair Value Measures (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R28": {
"firstAnchor": {
"ancestors": [
"us-gaap:PostemploymentBenefitsDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2332307 - Disclosure - Post-Employment Benefits (Tables)",
"role": "http://www.abbvie.com/role/PostEmploymentBenefitsTables",
"shortName": "Post-Employment Benefits (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"us-gaap:PostemploymentBenefitsDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R29": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2335308 - Disclosure - Equity (Tables)",
"role": "http://www.abbvie.com/role/EquityTables",
"shortName": "Equity (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:ProfitLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
"role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
"shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "-6",
"lang": "en-US",
"name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R30": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2348309 - Disclosure - Segment Information (Tables)",
"role": "http://www.abbvie.com/role/SegmentInformationTables",
"shortName": "Segment Information (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R31": {
"firstAnchor": {
"ancestors": [
"ix:continuation",
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "abbv:ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2402401 - Disclosure - Basis of Presentation (Details)",
"role": "http://www.abbvie.com/role/BasisofPresentationDetails",
"shortName": "Basis of Presentation (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"ix:continuation",
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ic06e9b84b6c747338436adc8b2c8aaec_D20210401-20210630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "abbv:ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R32": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:InterestExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2405402 - Disclosure - Supplemental Financial Information (Details)",
"role": "http://www.abbvie.com/role/SupplementalFinancialInformationDetails",
"shortName": "Supplemental Financial Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:InterestExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R33": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2408403 - Disclosure - Earnings Per Share (Details)",
"role": "http://www.abbvie.com/role/EarningsPerShareDetails",
"shortName": "Earnings Per Share (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "-6",
"lang": "en-US",
"name": "us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R34": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:PaymentsToAcquireOtherInvestments",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2410404 - Disclosure - Licensing, Acquisitions and Other Arrangements (Details)",
"role": "http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails",
"shortName": "Licensing, Acquisitions and Other Arrangements (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i1a083ce7270649bbb6e0ebd646810d4b_D20220101-20220331",
"decimals": "-6",
"lang": "en-US",
"name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R35": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:AccountsReceivableNetCurrent",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2413405 - Disclosure - Collaborations (Details)",
"role": "http://www.abbvie.com/role/CollaborationsDetails",
"shortName": "Collaborations (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ia036e6c593fa479fa0ca4a61783c2dc6_D20220101-20220630",
"decimals": "2",
"lang": "en-US",
"name": "abbv:CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty",
"reportCount": 1,
"unique": true,
"unitRef": "number",
"xsiNil": "false"
}
},
"R36": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfGoodwillTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "id5695becc3594da099d28f6bd485f543_I20211231",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:Goodwill",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2416406 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)",
"role": "http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails",
"shortName": "Goodwill and Intangible Assets - Goodwill (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfGoodwillTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": "-6",
"lang": "en-US",
"name": "us-gaap:GoodwillOtherIncreaseDecrease",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R37": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:FiniteLivedIntangibleAssetsGross",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2417407 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Net (Details)",
"role": "http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails",
"shortName": "Goodwill and Intangible Assets - Intangible Assets, Net (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "id5695becc3594da099d28f6bd485f543_I20211231",
"decimals": "-6",
"lang": "en-US",
"name": "us-gaap:FiniteLivedIntangibleAssetsGross",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R38": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i2c7df08664994f12aca1518baebbe045_I20220630",
"decimals": "-9",
"first": true,
"lang": "en-US",
"name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2420408 - Disclosure - Integration and Restructuring Plans (Details)",
"role": "http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
"shortName": "Integration and Restructuring Plans (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ib37c40029abd4cb58eba88c002702a40_D20220401-20220630",
"decimals": "-6",
"lang": "en-US",
"name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R39": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2423409 - Disclosure - Financial Instruments and Fair Value Measures - Financial Instruments (Details)",
"role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails",
"shortName": "Financial Instruments and Fair Value Measures - Financial Instruments (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1003004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)",
"role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited",
"shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R40": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ie3c18991cb0745f7bfde8bb5e68396df_I20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2424410 - Disclosure - Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)",
"role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"shortName": "Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i0ada3a46921346fd865f1babab324aeb_D20220401-20220630",
"decimals": "-6",
"lang": "en-US",
"name": "us-gaap:IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R41": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2425411 - Disclosure - Financial Instruments and Fair Value Measures - Fair Value Measures (Details)",
"role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails",
"shortName": "Financial Instruments and Fair Value Measures - Fair Value Measures (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i374e011a12484720b013a8ebf2f11a07_I20220630",
"decimals": "-6",
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R42": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ie0f761535955494a9972245ac0bfc828_I20220630",
"decimals": "3",
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
"reportCount": 1,
"unique": true,
"unitRef": "number",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2426412 - Disclosure - Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)",
"role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails",
"shortName": "Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ie0f761535955494a9972245ac0bfc828_I20220630",
"decimals": "3",
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
"reportCount": 1,
"unique": true,
"unitRef": "number",
"xsiNil": "false"
}
},
"R43": {
"firstAnchor": {
"ancestors": [
"us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
"us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2427413 - Disclosure - Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details)",
"role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails",
"shortName": "Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
"us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R44": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2428414 - Disclosure - Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)",
"role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
"shortName": "Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R45": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i934ebbdc3b45498680ed93ab96d279a4_D20220101-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "abbv:NumberOfPrincipalUSCustomers",
"reportCount": 1,
"unique": true,
"unitRef": "wholesaler",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2429415 - Disclosure - Financial Instruments and Fair Value Measures - Concentrations of Risk (Details)",
"role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails",
"shortName": "Financial Instruments and Fair Value Measures - Concentrations of Risk (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i934ebbdc3b45498680ed93ab96d279a4_D20220101-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "abbv:NumberOfPrincipalUSCustomers",
"reportCount": 1,
"unique": true,
"unitRef": "wholesaler",
"xsiNil": "false"
}
},
"R46": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i3f14360623824c9fa187ba70f2ae4df8_D20220101-20220131",
"decimals": "-8",
"first": true,
"lang": "en-US",
"name": "us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2430416 - Disclosure - Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)",
"role": "http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
"shortName": "Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i3f14360623824c9fa187ba70f2ae4df8_D20220101-20220131",
"decimals": "-8",
"first": true,
"lang": "en-US",
"name": "us-gaap:ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R47": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
"us-gaap:PostemploymentBenefitsDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i70516d291c55477c878b4b846af7180a_D20220401-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:DefinedBenefitPlanServiceCost",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2433417 - Disclosure - Post-Employment Benefits (Details)",
"role": "http://www.abbvie.com/role/PostEmploymentBenefitsDetails",
"shortName": "Post-Employment Benefits (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
"us-gaap:PostemploymentBenefitsDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i70516d291c55477c878b4b846af7180a_D20220401-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:DefinedBenefitPlanServiceCost",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R48": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2436418 - Disclosure - Equity - Stock-Based Compensation (Details)",
"role": "http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
"shortName": "Equity - Stock-Based Compensation (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:AllocatedShareBasedCompensationExpense",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R49": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ibd90914ea384473db98e01873e81a8f0_D20220101-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2437419 - Disclosure - Equity - Stock Options (Details)",
"role": "http://www.abbvie.com/role/EquityStockOptionsDetails",
"shortName": "Equity - Stock Options (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ibd90914ea384473db98e01873e81a8f0_D20220101-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1004005 - Statement - Condensed Consolidated Balance Sheets",
"role": "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
"shortName": "Condensed Consolidated Balance Sheets",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R50": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i30923fad127b4e44b3ef5a05f0f6aa16_D20220101-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2438420 - Disclosure - Equity - RSUs and Performance Shares (Details)",
"role": "http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
"shortName": "Equity - RSUs and Performance Shares (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i30923fad127b4e44b3ef5a05f0f6aa16_D20220101-20220630",
"decimals": "-5",
"first": true,
"lang": "en-US",
"name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R51": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfDividendsPayableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i29287228cbed45f6968865ac190732da_D20220623-20220623",
"decimals": "2",
"first": true,
"lang": "en-US",
"name": "us-gaap:CommonStockDividendsPerShareDeclared",
"reportCount": 1,
"unique": true,
"unitRef": "usdPerShare",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2439421 - Disclosure - Equity - Cash Dividends (Details)",
"role": "http://www.abbvie.com/role/EquityCashDividendsDetails",
"shortName": "Equity - Cash Dividends (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfDividendsPayableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i29287228cbed45f6968865ac190732da_D20220623-20220623",
"decimals": "2",
"first": true,
"lang": "en-US",
"name": "us-gaap:CommonStockDividendsPerShareDeclared",
"reportCount": 1,
"unique": true,
"unitRef": "usdPerShare",
"xsiNil": "false"
}
},
"R52": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:TreasuryStockValueAcquiredCostMethod",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2440422 - Disclosure - Equity - Stock Repurchase Program (Details)",
"role": "http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails",
"shortName": "Equity - Stock Repurchase Program (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ic64977043d5b42cdb5863680a3b5dc13_D20220101-20220630",
"decimals": "-6",
"lang": "en-US",
"name": "us-gaap:TreasuryStockSharesAcquired",
"reportCount": 1,
"unique": true,
"unitRef": "shares",
"xsiNil": "false"
}
},
"R53": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i8d2e3d15040b43b680868217bfddc553_I20220331",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2441423 - Disclosure - Equity - Accumulated Other Comprehensive Loss (Details)",
"role": "http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
"shortName": "Equity - Accumulated Other Comprehensive Loss (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i22b5f6d04f0a4544845c676987a1eeed_I20211231",
"decimals": "-6",
"lang": "en-US",
"name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R54": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:InterestIncomeExpenseNonoperatingNet",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2442424 - Disclosure - Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details)",
"role": "http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
"shortName": "Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ibfe42f85db284cd9a50c8b8604772997_D20220401-20220630",
"decimals": "-6",
"lang": "en-US",
"name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R55": {
"firstAnchor": {
"ancestors": [
"span",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "2",
"first": true,
"lang": "en-US",
"name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
"reportCount": 1,
"unique": true,
"unitRef": "number",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2444425 - Disclosure - Income Taxes (Details)",
"role": "http://www.abbvie.com/role/IncomeTaxesDetails",
"shortName": "Income Taxes (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "2",
"first": true,
"lang": "en-US",
"name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
"reportCount": 1,
"unique": true,
"unitRef": "number",
"xsiNil": "false"
}
},
"R56": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i64d6c36c72bf40409679cf0ae36b64d1_D20220101-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "abbv:LossContingencyIndividualPlaintiffLawsuitsNumber",
"reportCount": 1,
"unique": true,
"unitRef": "lawsuit",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2446426 - Disclosure - Legal Proceedings and Contingencies (Details)",
"role": "http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails",
"shortName": "Legal Proceedings and Contingencies (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"ix:continuation",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i64d6c36c72bf40409679cf0ae36b64d1_D20220101-20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "abbv:LossContingencyIndividualPlaintiffLawsuitsNumber",
"reportCount": 1,
"unique": true,
"unitRef": "lawsuit",
"xsiNil": "false"
}
},
"R57": {
"firstAnchor": null,
"groupType": "disclosure",
"isDefault": "false",
"longName": "2449427 - Disclosure - Segment Information - Additional Information (Details)",
"role": "http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails",
"shortName": "Segment Information - Additional Information (Details)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R58": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i41938fd146174f26bcca56dd5e673fce_D20220401-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:Revenues",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2450428 - Disclosure - Segment Information - Disaggregation of Revenue (Details)",
"role": "http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails",
"shortName": "Segment Information - Disaggregation of Revenue (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"ix:continuation",
"ix:continuation",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i676449a933204a9cb64a6f54570b2d60_D20220401-20220630",
"decimals": "-6",
"lang": "en-US",
"name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:CommonStockParOrStatedValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "usdPerShare",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1005006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
"role": "http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
"shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "ic91a21f1f5374fe1ac3b33ad3aaf6563_I20220630",
"decimals": "INF",
"first": true,
"lang": "en-US",
"name": "us-gaap:CommonStockParOrStatedValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "usdPerShare",
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "if1816b7eac954956b4765afd462e3f73_I20201231",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1006007 - Statement - Condensed Consolidated Statements of Equity (Unaudited)",
"role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
"shortName": "Condensed Consolidated Statements of Equity (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "if0fc5d280fb74f1eb96d3958d3310a50_I20201231",
"decimals": "-6",
"lang": "en-US",
"name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": "-6",
"first": true,
"lang": "en-US",
"name": "us-gaap:ProfitLoss",
"reportCount": 1,
"unitRef": "usd",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
"role": "http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
"shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"td",
"tr",
"table",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": "-6",
"lang": "en-US",
"name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
"reportCount": 1,
"unique": true,
"unitRef": "usd",
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "2101101 - Disclosure - Basis of Presentation",
"role": "http://www.abbvie.com/role/BasisofPresentation",
"shortName": "Basis of Presentation",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"div",
"body",
"html"
],
"baseRef": "abbv-20220630.htm",
"contextRef": "i733b9e9e77d74a77b0f95ef628718728_D20220101-20220630",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 127,
"tag": {
"abbv_AccumulatedNetGainLossFromNetInvestmentHedgesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated Net Gain (Loss) From Net Investment Hedges",
"label": "Accumulated Net Gain (Loss) From Net Investment Hedges [Member]",
"terseLabel": "Net investment hedging activities"
}
}
},
"localname": "AccumulatedNetGainLossFromNetInvestmentHedgesMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "domainItemType"
},
"abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Licensing, Acquisitions, and Other Arrangements",
"terseLabel": "Licensing, Acquisitions, and Other Arrangements"
}
}
},
"localname": "AcquisitionsCollaborationsAndOtherArrangementsDisclosureAbstract",
"nsuri": "http://www.abbvie.com/20220630",
"xbrltype": "stringItemType"
},
"abbv_AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for acquisitions, collaborations and other arrangements of the entity.",
"label": "Acquisitions Collaborations and Other Arrangements Disclosure [Text Block]",
"terseLabel": "Licensing, Acquisitions, and Other Arrangements"
}
}
},
"localname": "AcquisitionsCollaborationsAndOtherArrangementsDisclosureTextBlock",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangements"
],
"xbrltype": "textBlockItemType"
},
"abbv_AestheticsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Aesthetics, a key product portfolio of the entity.",
"label": "Aesthetics [Member]",
"terseLabel": "Aesthetics"
}
}
},
"localname": "AestheticsMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_AllerganIntegrationPlanMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to the Allergan integration plan.",
"label": "Allergan Integration Plan [Member]",
"terseLabel": "Allergan integration plan"
}
}
},
"localname": "AllerganIntegrationPlanMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
"http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
],
"xbrltype": "domainItemType"
},
"abbv_AlphaganCombiganMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Alphagan/Combigan, a product of the entity.",
"label": "Alphagan/Combigan [Member]",
"terseLabel": "Alphagan/Combigan"
}
}
},
"localname": "AlphaganCombiganMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to AndroGel antitrust litigation filed under King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al.",
"label": "AndroGel Antitrust Litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al. [Member]",
"terseLabel": "AndroGel antitrust litigation, King Drug Co. of Florence, Inc., et al. v. AbbVie Inc., et al."
}
}
},
"localname": "AndroGelAntitrustLitigationKingDrugCoOfFlorenceIncEtAlVAbbVieIncEtAlMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "domainItemType"
},
"abbv_BotoxCosmeticMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Botox Cosmetic, a product of the entity.",
"label": "Botox Cosmetic [Member]",
"terseLabel": "Botox Cosmetic"
}
}
},
"localname": "BotoxCosmeticMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_BotoxTherapeuticMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Botox Therapeutic, a product of the entity.",
"label": "Botox Therapeutic [Member]",
"terseLabel": "Botox Therapeutic"
}
}
},
"localname": "BotoxTherapeuticMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_BystolicAntitrustLitigationMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Bystolic antitrust litigation.",
"label": "Bystolic Antitrust Litigation [Member]",
"terseLabel": "Bystolic antitrust litigation"
}
}
},
"localname": "BystolicAntitrustLitigationMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "domainItemType"
},
"abbv_CollaborativeArrangementMilestoneMethodPaymentsReceivable": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The maximum milestone payments that may be received by the entity based on the achievement of specified events under a collaborative arrangement.",
"label": "Collaborative Arrangement Milestone Method Payments Receivable",
"terseLabel": "Milestone payments"
}
}
},
"localname": "CollaborativeArrangementMilestoneMethodPaymentsReceivable",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails"
],
"xbrltype": "monetaryItemType"
},
"abbv_CollaborativeArrangementsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Collaborative Arrangements",
"label": "Collaborative Arrangements [Abstract]",
"terseLabel": "Collaborative Arrangements [Abstract]"
}
}
},
"localname": "CollaborativeArrangementsAbstract",
"nsuri": "http://www.abbvie.com/20220630",
"xbrltype": "stringItemType"
},
"abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the percentage of share in collaboration development costs responsible by the entity under cost sharing arrangement.",
"label": "Collaborative Arrangements Percentage Of Share Of Development Costs",
"terseLabel": "Share of collaboration development costs responsible by the entity (as a percent)"
}
}
},
"localname": "CollaborativeArrangementsPercentageOfShareOfDevelopmentCosts",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails"
],
"xbrltype": "percentItemType"
},
"abbv_CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the percentage of share in collaboration development costs responsible by Janssen under cost sharing arrangement.",
"label": "Collaborative Arrangements Percentage Of Share Of Development Costs Responsible By Third Party",
"terseLabel": "Share of collaboration development costs responsible by Janssen (as a percent)"
}
}
},
"localname": "CollaborativeArrangementsPercentageOfShareOfDevelopmentCostsResponsibleByThirdParty",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails"
],
"xbrltype": "percentItemType"
},
"abbv_CostofGoodsAndServicesSoldFromCollaborativeArrangements": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of costs of goods and services sold arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.",
"label": "Cost of Goods And Services Sold From Collaborative Arrangements",
"terseLabel": "Collaboration counterparty's share of collaborative arrangement expenses (included in cost of products sold)"
}
}
},
"localname": "CostofGoodsAndServicesSoldFromCollaborativeArrangements",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails"
],
"xbrltype": "monetaryItemType"
},
"abbv_CreonMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Creon, a product of the entity.",
"label": "Creon [Member]",
"terseLabel": "Creon"
}
}
},
"localname": "CreonMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_December2018StockRepurchaseAuthorizationMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "December 2018 Stock Repurchase Authorization",
"label": "December 2018 Stock Repurchase Authorization [Member]",
"terseLabel": "December 2018 Stock Repurchase Authorization"
}
}
},
"localname": "December2018StockRepurchaseAuthorizationMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
],
"xbrltype": "domainItemType"
},
"abbv_DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit": {
"auth_ref": [
],
"calculation": {
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
"order": 1.0,
"parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of amortization of actuarial losses and prior service costs included in the calculation of net periodic pension benefit cost.",
"label": "Defined Benefit Plan, Amortization Of Actuarial Gain (Loss), Prior Service Cost (Credit)",
"negatedLabel": "Amortization of actuarial loss"
}
}
},
"localname": "DefinedBenefitPlanAmortizationOfActuarialGainLossPriorServiceCostCredit",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
],
"xbrltype": "monetaryItemType"
},
"abbv_DuodopaMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Duodopa, a product of the entity.",
"label": "Duodopa [Member]",
"terseLabel": "Duodopa"
}
}
},
"localname": "DuodopaMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_ElliottAssociatesL.P.Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Elliot Associates, LP.",
"label": "Elliott Associates, L.P. [Member]",
"terseLabel": "Elliott Associates, L.P."
}
}
},
"localname": "ElliottAssociatesL.P.Member",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "domainItemType"
},
"abbv_EyeCareMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Eye Care, a key product portfolio of the entity.",
"label": "Eye Care [Member]",
"terseLabel": "Eye Care"
}
}
},
"localname": "EyeCareMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_FloatingRateTermLoanTrancheDueMay2025Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Floating Rate Term Loan Tranche Due May 2025",
"label": "Floating Rate Term Loan Tranche Due May 2025 [Member]",
"terseLabel": "Floating rate notes due 2025"
}
}
},
"localname": "FloatingRateTermLoanTrancheDueMay2025Member",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "domainItemType"
},
"abbv_FloatingRateTermLoanTrancheDueMay2025RefinancedMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Floating Rate Term Loan Tranche Due May 2025, Refinanced",
"label": "Floating Rate Term Loan Tranche Due May 2025, Refinanced [Member]",
"terseLabel": "Floating rate notes due 2025, refinanced"
}
}
},
"localname": "FloatingRateTermLoanTrancheDueMay2025RefinancedMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "domainItemType"
},
"abbv_GenentechInc.Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Genentech, Inc. [Member]",
"label": "Genentech, Inc. [Member]",
"verboseLabel": "Genentech, Inc."
}
}
},
"localname": "GenentechInc.Member",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/CollaborationsTables"
],
"xbrltype": "domainItemType"
},
"abbv_HUMIRAMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to HUMIRA, a product of the entity.",
"label": "H U M I R A [Member]",
"terseLabel": "Humira"
}
}
},
"localname": "HUMIRAMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails",
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_HematologicOncologyMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Hematologic Oncology, a key product portfolio of the entity.",
"label": "Hematologic Oncology [Member]",
"terseLabel": "Hematologic Oncology"
}
}
},
"localname": "HematologicOncologyMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to lawsuits filed alleging that AbbVie\u2019s settlements with biosimilar manufacturers and AbbVie\u2019s Humira patent portfolio violated state and federal antitrust laws.",
"label": "Humira Antitrust Litigation, In re: Humira (Adalimumab) Antitrust Litigation [Member]",
"terseLabel": "Humira antitrust litigation, In re: Humira (Adalimumab) Antitrust Litigation"
}
}
},
"localname": "HumiraAntitrustLitigationInReHumiraAdalimumabAntitrustLitigationMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "domainItemType"
},
"abbv_ImbruvicaMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Imbruvica, a product of the entity.",
"label": "Imbruvica [Member]",
"terseLabel": "Imbruvica"
}
}
},
"localname": "ImbruvicaMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_ImmunologyMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Immunology, a key product portfolio of the entity.",
"label": "Immunology [Member]",
"terseLabel": "Immunology"
}
}
},
"localname": "ImmunologyMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_JanssenBiotechIncMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the information pertains to the entity Janssen Biotech Inc.",
"label": "Janssen Biotech Inc [Member]",
"terseLabel": "Janssen Biotech Inc."
}
}
},
"localname": "JanssenBiotechIncMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/CollaborationsTables"
],
"xbrltype": "domainItemType"
},
"abbv_JuvedermCollectionMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Juvederm Collection, a product of the entity.",
"label": "Juvederm Collection [Member]",
"terseLabel": "Juvederm Collection"
}
}
},
"localname": "JuvedermCollectionMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_JuvisePharmaceuticalsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Juvise Pharmaceuticals",
"label": "Juvise Pharmaceuticals [Member]",
"terseLabel": "Juvise Pharmaceuticals"
}
}
},
"localname": "JuvisePharmaceuticalsMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "domainItemType"
},
"abbv_KeyProductPortfolioAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information concerning the company's portfolios of key products.",
"label": "Key Product Portfolio [Axis]",
"terseLabel": "Key Product Portfolio [Axis]"
}
}
},
"localname": "KeyProductPortfolioAxis",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "stringItemType"
},
"abbv_KeyProductPortfolioDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "[Domain] for Information concerning the company's portfolios of key products.",
"label": "Key Product Portfolio [Domain]",
"terseLabel": "Key Product Portfolio [Domain]"
}
}
},
"localname": "KeyProductPortfolioDomain",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_LinzessConstellaMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Linzess/Constella, a product of the entity.",
"label": "Linzess/Constella [Member]",
"terseLabel": "Linzess/Constella"
}
}
},
"localname": "LinzessConstellaMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure": {
"auth_ref": [
],
"calculation": {
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the fair value amount of obligation related to long-term debt (excluding convertible debt) and capital leases, the portion which is due in one year or less in the future.",
"label": "Long Term Debt and Capital Lease Obligations Current Fair Value Disclosure",
"verboseLabel": "Current portion of long-term debt and finance lease obligations, excluding fair value hedges"
}
}
},
"localname": "LongTermDebtAndCapitalLeaseObligationsCurrentFairValueDisclosure",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"abbv_LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure": {
"auth_ref": [
],
"calculation": {
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the fair value amount of as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year from the balance sheet date or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer plus capital lease obligations due to be paid more than one year after the balance sheet date.",
"label": "Long Term Debt and Capital Lease Obligations Fair Value Disclosure",
"verboseLabel": "Long-term debt and finance lease obligations, excluding fair value hedges"
}
}
},
"localname": "LongTermDebtAndCapitalLeaseObligationsFairValueDisclosure",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"abbv_LossContingencyIndividualPlaintiffLawsuitsNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the number of individual plaintiff lawsuits filed, pertaining to a loss contingency during the period.",
"label": "Loss Contingency Individual Plaintiff Lawsuits Number",
"terseLabel": "Number of individual plaintiff lawsuits"
}
}
},
"localname": "LossContingencyIndividualPlaintiffLawsuitsNumber",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "integerItemType"
},
"abbv_LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the number of generic companies with whom certain litigation related agreements are entered into that violated federal and state antitrust laws and state consumer protection and unjust enrichment laws.",
"label": "Loss Contingency Number of Generic Companies as Counterparty of Litigation Related Agreements Violated Certain Laws",
"terseLabel": "Number of generic companies with whom certain litigation related agreements were entered into"
}
}
},
"localname": "LossContingencyNumberOfGenericCompaniesAsCounterpartyOfLitigationRelatedAgreementsViolatedCertainLaws",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "integerItemType"
},
"abbv_LossContingencyPurportedClassActionsNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the number of purported class actions filed, pertaining to a loss contingency during the period.",
"label": "Loss Contingency Purported Class Actions Number",
"terseLabel": "Number of purported class actions"
}
}
},
"localname": "LossContingencyPurportedClassActionsNumber",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "integerItemType"
},
"abbv_LumiganGanfortMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Lumigan/Ganfort, a product of the entity.",
"label": "Lumigan/Ganfort [Member]",
"terseLabel": "Lumigan/Ganfort"
}
}
},
"localname": "LumiganGanfortMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_MAVYRETMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to MAVYRET, a product of the entity.",
"label": "MAVYRET [Member]",
"terseLabel": "Mavyret"
}
}
},
"localname": "MAVYRETMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_NeuroscienceMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Neuroscience, a key product portfolio of the entity.",
"label": "Neuroscience [Member]",
"terseLabel": "Neuroscience"
}
}
},
"localname": "NeuroscienceMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_NiaspanMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Niaspan, a product of the entity.",
"label": "Niaspan [Member]",
"terseLabel": "Niaspan"
}
}
},
"localname": "NiaspanMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "domainItemType"
},
"abbv_NonCashLitigationReserveAdjustmentsNetOfCashPayments": {
"auth_ref": [
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 9.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Non-cash litigation reserve adjustments, net of cash payments",
"label": "Non-cash litigation reserve adjustments, net of cash payments",
"terseLabel": "Non-cash litigation reserve adjustments, net of cash payments"
}
}
},
"localname": "NonCashLitigationReserveAdjustmentsNetOfCashPayments",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"abbv_NumberOfPrincipalUSCustomers": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the number of principal U.S. customers of the entity.",
"label": "Number of Principal US Customers",
"terseLabel": "Number of principal customers"
}
}
},
"localname": "NumberOfPrincipalUSCustomers",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
],
"xbrltype": "integerItemType"
},
"abbv_OtherAestheticsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Other Aesthetics products.",
"label": "Other Aesthetics [Member]",
"terseLabel": "Other Aesthetics"
}
}
},
"localname": "OtherAestheticsMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax": {
"auth_ref": [
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
"order": 4.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instruments and nonderivative instruments designated and qualifying as net investment hedge.",
"label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), After Reclassification and Tax",
"terseLabel": "Net investment hedging activities, net of tax expense (benefit) of $146 for the three months and $183 for the six months ended June 30, 2022 and $(31) for the three months and $72 for the six months ended June 30, 2021"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossAfterReclassificationandTax",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
],
"xbrltype": "monetaryItemType"
},
"abbv_OtherComprehensiveIncomeLossNetInvestmentHedgeTax": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on derivative instruments and nonderivative instruments designated and qualifying as net investment hedge.",
"label": "Other Comprehensive Income (Loss), Net Investment Hedge, Tax",
"terseLabel": "Net investment hedging activities, tax expense (benefit)"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeTax",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"
],
"xbrltype": "monetaryItemType"
},
"abbv_OtherExpensesFromCollaborativeArrangements": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of other expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.",
"label": "Other Expenses From Collaborative Arrangements",
"terseLabel": "Global - AbbVie's share of other costs (included in respective line items)"
}
}
},
"localname": "OtherExpensesFromCollaborativeArrangements",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails"
],
"xbrltype": "monetaryItemType"
},
"abbv_OtherEyeCareMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Other Eye Care products.",
"label": "Other Eye Care [Member]",
"terseLabel": "Other Eye Care"
}
}
},
"localname": "OtherEyeCareMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_OtherKeyProductsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to other key products of the entity.",
"label": "Other Key Products [Member]",
"terseLabel": "Other Key Products"
}
}
},
"localname": "OtherKeyProductsMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_OtherNeuroscienceMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Other Neuroscience products.",
"label": "Other Neuroscience [Member]",
"terseLabel": "Other Neuroscience"
}
}
},
"localname": "OtherNeuroscienceMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_OtherProductsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to other products of the entity not specified anywhere.",
"label": "Other Products [Member]",
"terseLabel": "All other"
}
}
},
"localname": "OtherProductsMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_OtherRestructuringPlansMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents other restructuring plans.",
"label": "Other Restructuring Plans [Member]",
"terseLabel": "Other restructuring"
}
}
},
"localname": "OtherRestructuringPlansMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
"http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
],
"xbrltype": "domainItemType"
},
"abbv_PotentialPaymentsUnderAgreementCertainMilestones": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of additional payments that could be required for the achievement of certain milestones under a product agreement during the period.",
"label": "Potential Payments under Agreement Certain Milestones",
"terseLabel": "Potential payments under agreement certain milestones"
}
}
},
"localname": "PotentialPaymentsUnderAgreementCertainMilestones",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "monetaryItemType"
},
"abbv_PrescriptionDrugAbuseLitigationInStateCourtsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Prescription Drug Abuse Litigation In State Courts",
"label": "Prescription Drug Abuse Litigation In State Courts [Member]",
"terseLabel": "Prescription drug abuse litigation in state courts"
}
}
},
"localname": "PrescriptionDrugAbuseLitigationInStateCourtsMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "domainItemType"
},
"abbv_PrescriptionDrugAbuseLitigationMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to prescription drug abuse litigation.",
"label": "Prescription Drug Abuse Litigation [Member]",
"terseLabel": "Prescription drug abuse litigation"
}
}
},
"localname": "PrescriptionDrugAbuseLitigationMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "domainItemType"
},
"abbv_PrincipalUSCustomersMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Principal US Customers",
"label": "Principal US Customers [Member]",
"terseLabel": "Principal US customers"
}
}
},
"localname": "PrincipalUSCustomersMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
],
"xbrltype": "domainItemType"
},
"abbv_ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents estimated probability of payment for royalties excluding approved indications.",
"label": "Probability of Payment for Royalties Excluding Approved Indications [Member]",
"terseLabel": "Probability of payment for royalties excluding early stage or approved indications"
}
}
},
"localname": "ProbabilityofPaymentforRoyaltiesExcludingApprovedIndicationsMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
],
"xbrltype": "domainItemType"
},
"abbv_ProbabilityofPaymentforRoyaltiesbyIndicationMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents probability of payment for royalties by indication.",
"label": "Probability of Payment for Royalties by Indication [Member]",
"terseLabel": "Probability of payment for royalties by indication"
}
}
},
"localname": "ProbabilityofPaymentforRoyaltiesbyIndicationMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
],
"xbrltype": "domainItemType"
},
"abbv_ProbabilityofPaymentforUnachievedMilestonesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents the probability of payment for unachieved milestones",
"label": "Probability of Payment for Unachieved Milestones [Member]",
"terseLabel": "Probability of payment for unachieved milestones"
}
}
},
"localname": "ProbabilityofPaymentforUnachievedMilestonesMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
],
"xbrltype": "domainItemType"
},
"abbv_ProjectedYearofPaymentsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents projected year of payments.",
"label": "Projected Year of Payments [Member]",
"terseLabel": "Projected year of payments"
}
}
},
"localname": "ProjectedYearofPaymentsMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
],
"xbrltype": "domainItemType"
},
"abbv_PutativeClassActionLawsuitIndividualNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents number of the number of individual putative class action lawsuit.",
"label": "Putative Class Action Lawsuit Individual Number",
"terseLabel": "Number of individual putative class action lawsuits"
}
}
},
"localname": "PutativeClassActionLawsuitIndividualNumber",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "integerItemType"
},
"abbv_QuliptaMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Qulipta",
"label": "Qulipta [Member]",
"terseLabel": "Qulipta"
}
}
},
"localname": "QuliptaMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_RINVOQMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to RINVOQ, a product of the entity.",
"label": "RINVOQ [Member]",
"terseLabel": "Rinvoq"
}
}
},
"localname": "RINVOQMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Reclassification of development milestone expense from research and development expense",
"label": "Reclassification of development milestone expense from research and development expense",
"terseLabel": "Reclassification of development milestone expense from research and development expense"
}
}
},
"localname": "ReclassificationOfDevelopmentMilestoneExpenseFromResearchAndDevelopmentExpense",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/BasisofPresentationDetails"
],
"xbrltype": "monetaryItemType"
},
"abbv_ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "represents reclassification of development milestone expense associated with licensing and collaboration arrangements to IPR&D and milestones expense.",
"label": "Reclassification of development milestone expense to IPR&D and milestones expense",
"terseLabel": "Reclassification of development milestone expense to IPR&D and milestones expense"
}
}
},
"localname": "ReclassificationOfDevelopmentMilestoneExpenseToIPRDAndMilestonesExpense",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/BasisofPresentationDetails"
],
"xbrltype": "monetaryItemType"
},
"abbv_ResearchAndDevelopmentExpenseFromCollaborativeArrangements": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of research and development expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.",
"label": "Research And Development Expense From Collaborative Arrangements",
"terseLabel": "AbbVie's share of development costs (included in R&D)"
}
}
},
"localname": "ResearchAndDevelopmentExpenseFromCollaborativeArrangements",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails"
],
"xbrltype": "monetaryItemType"
},
"abbv_RestasisMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Restasis, a product of the entity.",
"label": "Restasis [Member]",
"terseLabel": "Restasis"
}
}
},
"localname": "RestasisMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_RestrictedStockUnitsAndPerformanceSharesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Restricted Stock Units And Performance Shares [Member]",
"label": "Restricted Stock Units And Performance Shares [Member]",
"terseLabel": "RSUs and Performance Shares"
}
}
},
"localname": "RestrictedStockUnitsAndPerformanceSharesMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails"
],
"xbrltype": "domainItemType"
},
"abbv_RestructuringReserveCashSettledRestructuringGainsLosses": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The change in the restructuring reserve related to the amount of restructuring gains (losses) during the period that are expected to be cash settled.",
"label": "Restructuring Reserve Cash Settled Restructuring Gains (Losses)",
"verboseLabel": "Restructuring charges"
}
}
},
"localname": "RestructuringReserveCashSettledRestructuringGainsLosses",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
],
"xbrltype": "monetaryItemType"
},
"abbv_RestructuringReservePeriodCashSettledAndOtherAdjustments": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The change in the restructuring reserve related to the amount of cash paid and other adjustments during the period.",
"label": "Restructuring Reserve Period Cash Settled and Other Adjustments",
"negatedLabel": "Payments and other adjustments"
}
}
},
"localname": "RestructuringReservePeriodCashSettledAndOtherAdjustments",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
],
"xbrltype": "monetaryItemType"
},
"abbv_SKYRIZIMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to SKYRIZI, a product of the entity.",
"label": "SKYRIZI [Member]",
"terseLabel": "Skyrizi"
}
}
},
"localname": "SKYRIZIMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_Sec0.750SeniorNotesDue2027Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Sec 0.750 Senior Notes Due 2027 [Member]",
"label": "Sec 0.750 Senior Notes Due 2027 [Member]",
"terseLabel": "Sec 0.750 Senior Notes Due 2027"
}
}
},
"localname": "Sec0.750SeniorNotesDue2027Member",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "domainItemType"
},
"abbv_Sec1.250SeniorNotesdue2031Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Sec 1.250 Senior Notes due 2031 [Member]",
"label": "Sec 1.250 Senior Notes due 2031 [Member]",
"terseLabel": "Sec 1.250 Senior Notes due 2031"
}
}
},
"localname": "Sec1.250SeniorNotesdue2031Member",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "domainItemType"
},
"abbv_Sec1.375SeniorNotesDue2024Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Sec 1.375 Senior Notes Due 2024 [Member]",
"label": "Sec 1.375 Senior Notes Due 2024 [Member]",
"terseLabel": "Sec 1.375 Senior Notes Due 2024"
}
}
},
"localname": "Sec1.375SeniorNotesDue2024Member",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "domainItemType"
},
"abbv_Sec1250SeniorNotesDue2024Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Sec 1.250 Senior Notes Due 2024",
"label": "Sec 1.250 Senior Notes Due 2024 [Member]",
"terseLabel": "Sec 1.250 Senior Notes Due 2024"
}
}
},
"localname": "Sec1250SeniorNotesDue2024Member",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "domainItemType"
},
"abbv_Sec1500SeniorNotesDue2023Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Sec 1.500 Senior Notes Due 2023",
"label": "Sec 1.500 Senior Notes Due 2023 [Member]",
"terseLabel": "Sec 1.500 Senior Notes Due 2023"
}
}
},
"localname": "Sec1500SeniorNotesDue2023Member",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "domainItemType"
},
"abbv_Sec2.125SeniorNotesdue2028Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Sec 2.125 Senior Notes due 2028 [Member]",
"label": "Sec 2.125 Senior Notes due 2028 [Member]",
"terseLabel": "Sec 2.125 Senior Notes due 2028"
}
}
},
"localname": "Sec2.125SeniorNotesdue2028Member",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "domainItemType"
},
"abbv_Sec2125SeniorNotesDue2029Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Sec 2.125 Senior Notes Due 2029",
"label": "Sec 2.125 Senior Notes Due 2029 [Member]",
"terseLabel": "Sec 2.125 Senior Notes Due 2029"
}
}
},
"localname": "Sec2125SeniorNotesDue2029Member",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "domainItemType"
},
"abbv_Sec2625SeniorNotesDue2028Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Sec 2.625 Senior Notes Due 2028",
"label": "Sec 2.625 Senior Notes Due 2028 [Member]",
"terseLabel": "Sec 2.625 Senior Notes Due 2028"
}
}
},
"localname": "Sec2625SeniorNotesDue2028Member",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "domainItemType"
},
"abbv_SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of selling, general and administrative expenses arising from collaborative arrangements, including, but not limited to, profit-sharing, cost-sharing, royalties and other shared costs incurred under the collaboration terms.",
"label": "Selling, General And Administrative Expense From Collaborative Arrangements",
"terseLabel": "AbbVie's share of sales and marketing costs from U.S. collaboration (included in SG&A)"
}
}
},
"localname": "SellingGeneralAndAdministrativeExpenseFromCollaborativeArrangements",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails"
],
"xbrltype": "monetaryItemType"
},
"abbv_SeniorEuroNotesDue2021At0.500PercentMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Senior Euro Notes Due 2021 At 0.500 Percent",
"label": "Senior Euro Notes Due 2021 At 0.500 Percent [Member]",
"terseLabel": "0.50% senior euro notes due 2021"
}
}
},
"localname": "SeniorEuroNotesDue2021At0.500PercentMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "domainItemType"
},
"abbv_SeniorNotes2.30PercentDue2021Member": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to the 2.30% Unsecured Senior Notes Due 2021.",
"label": "Senior Notes 2.30 Percent Due 2021 [Member]",
"terseLabel": "2.30% senior notes due 2021"
}
}
},
"localname": "SeniorNotes2.30PercentDue2021Member",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "domainItemType"
},
"abbv_SeniorNotesDue2022At3.250PercentMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Senior Notes Due 2022 At 3.250 Percent",
"label": "Senior Notes Due 2022 At 3.250 Percent [Member]",
"terseLabel": "3.25% senior notes due 2022"
}
}
},
"localname": "SeniorNotesDue2022At3.250PercentMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "domainItemType"
},
"abbv_SeniorNotesDue2022At3.450PercentMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Senior Notes Due 2022 At 3.450 Percent",
"label": "Senior Notes Due 2022 At 3.450 Percent [Member]",
"terseLabel": "3.45% senior notes due 2022"
}
}
},
"localname": "SeniorNotesDue2022At3.450PercentMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "domainItemType"
},
"abbv_SeniorNotesDueInMay2021AtFloatingRatesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Senior Notes Due in May 2021 At Floating Rates",
"label": "Senior Notes Due in May 2021 At Floating Rates [Member]",
"terseLabel": "Floating senior notes due 2021"
}
}
},
"localname": "SeniorNotesDueInMay2021AtFloatingRatesMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"abbv_SupplementalFinancialInformationDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Supplemental Financial Information",
"terseLabel": "Supplemental Financial Information"
}
}
},
"localname": "SupplementalFinancialInformationDisclosureAbstract",
"nsuri": "http://www.abbvie.com/20220630",
"xbrltype": "stringItemType"
},
"abbv_SyndesiMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Syndesi",
"label": "Syndesi [Member]",
"terseLabel": "Syndesi"
}
}
},
"localname": "SyndesiMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "domainItemType"
},
"abbv_TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Treasury Rate Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
"label": "Treasury Lock Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
"terseLabel": "Pre-tax gains (losses) to be transferred into interest expense, net for treasury rate lock agreement cash flow hedges during the next 12 months"
}
}
},
"localname": "TreasuryLockCashFlowHedgeGainLosstobeReclassifiedDuringNext12MonthsNet",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"abbv_UbrelvyMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Ubrelvy, a product of the entity.",
"label": "Ubrelvy [Member]",
"terseLabel": "Ubrelvy"
}
}
},
"localname": "UbrelvyMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_VENCLEXTAMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to VENCLEXTA, a product of the entity.",
"label": "VENCLEXTA [Member]",
"terseLabel": "Venclexta"
}
}
},
"localname": "VENCLEXTAMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"abbv_VraylarMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Represents information pertaining to Vraylar, a product of the entity.",
"label": "Vraylar [Member]",
"terseLabel": "Vraylar"
}
}
},
"localname": "VraylarMember",
"nsuri": "http://www.abbvie.com/20220630",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"country_US": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "UNITED STATES",
"terseLabel": "United States"
}
}
},
"localname": "US",
"nsuri": "http://xbrl.sec.gov/country/2021",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"dei_AmendmentFlag": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag",
"terseLabel": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code",
"terseLabel": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Cover page.",
"label": "Cover [Abstract]",
"terseLabel": "Cover [Abstract]"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"xbrltype": "stringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date",
"terseLabel": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus",
"terseLabel": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus",
"terseLabel": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date",
"terseLabel": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r670"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report",
"terseLabel": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r671"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report",
"terseLabel": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type",
"terseLabel": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntitiesTable": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Container to assemble all relevant information about each entity associated with the document instance",
"label": "Entities [Table]",
"terseLabel": "Entities [Table]"
}
}
},
"localname": "EntitiesTable",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "stringItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One",
"terseLabel": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town",
"terseLabel": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code",
"terseLabel": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address, State or Province",
"terseLabel": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r672"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key",
"terseLabel": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock, Shares Outstanding",
"terseLabel": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status",
"terseLabel": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r672"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company",
"terseLabel": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Entity File Number",
"terseLabel": "Entity File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r672"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category",
"terseLabel": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code",
"terseLabel": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInformationLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Entity Information [Line Items]",
"terseLabel": "Entity Information"
}
}
},
"localname": "EntityInformationLineItems",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "stringItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r674"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current",
"terseLabel": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityListingsExchangeAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
"label": "Entity Listings, Exchange [Axis]",
"terseLabel": "Entity Listings, Exchange [Axis]"
}
}
},
"localname": "EntityListingsExchangeAxis",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "stringItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r672"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name",
"terseLabel": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r672"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company",
"terseLabel": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r672"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business",
"terseLabel": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r672"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number",
"terseLabel": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "employerIdItemType"
},
"dei_ExchangeDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
"label": "Exchange [Domain]",
"terseLabel": "Exchange [Domain]"
}
}
},
"localname": "ExchangeDomain",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "domainItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number",
"terseLabel": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "normalizedStringItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r668"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Title of 12(b) Security",
"terseLabel": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r669"
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name",
"terseLabel": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_TradingSymbol": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol",
"terseLabel": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "tradingSymbolItemType"
},
"exch_XCHI": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "CHICAGO STOCK EXCHANGE, INC [Member]",
"terseLabel": "CHICAGO STOCK EXCHANGE, INC"
}
}
},
"localname": "XCHI",
"nsuri": "http://xbrl.sec.gov/exch/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "domainItemType"
},
"exch_XNYS": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "NEW YORK STOCK EXCHANGE, INC. [Member]",
"terseLabel": "NEW YORK STOCK EXCHANGE, INC."
}
}
},
"localname": "XNYS",
"nsuri": "http://xbrl.sec.gov/exch/2021",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "domainItemType"
},
"srt_CounterpartyNameAxis": {
"auth_ref": [
"r51",
"r53",
"r117",
"r118",
"r276",
"r298"
],
"lang": {
"en-us": {
"role": {
"label": "Counterparty Name [Axis]",
"terseLabel": "Counterparty Name [Axis]"
}
}
},
"localname": "CounterpartyNameAxis",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/CollaborationsTables",
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "stringItemType"
},
"srt_LitigationCaseAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Litigation Case [Axis]",
"terseLabel": "Litigation Case [Axis]"
}
}
},
"localname": "LitigationCaseAxis",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "stringItemType"
},
"srt_LitigationCaseTypeDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Litigation Case [Domain]",
"terseLabel": "Litigation Case Type [Domain]"
}
}
},
"localname": "LitigationCaseTypeDomain",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "domainItemType"
},
"srt_MajorCustomersAxis": {
"auth_ref": [
"r194",
"r312",
"r315",
"r631"
],
"lang": {
"en-us": {
"role": {
"label": "Customer [Axis]",
"terseLabel": "Customer [Axis]"
}
}
},
"localname": "MajorCustomersAxis",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
],
"xbrltype": "stringItemType"
},
"srt_MaximumMember": {
"auth_ref": [
"r275",
"r297",
"r395",
"r400",
"r573",
"r574",
"r575",
"r576",
"r577",
"r578",
"r580",
"r628",
"r632",
"r666",
"r667"
],
"lang": {
"en-us": {
"role": {
"label": "Maximum [Member]",
"terseLabel": "Maximum"
}
}
},
"localname": "MaximumMember",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails",
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "domainItemType"
},
"srt_MinimumMember": {
"auth_ref": [
"r275",
"r297",
"r395",
"r400",
"r573",
"r574",
"r575",
"r576",
"r577",
"r578",
"r580",
"r628",
"r632",
"r666",
"r667"
],
"lang": {
"en-us": {
"role": {
"label": "Minimum [Member]",
"terseLabel": "Minimum"
}
}
},
"localname": "MinimumMember",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
],
"xbrltype": "domainItemType"
},
"srt_NameOfMajorCustomerDomain": {
"auth_ref": [
"r194",
"r312",
"r315",
"r631"
],
"lang": {
"en-us": {
"role": {
"label": "Customer [Domain]",
"terseLabel": "Customer [Domain]"
}
}
},
"localname": "NameOfMajorCustomerDomain",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
],
"xbrltype": "domainItemType"
},
"srt_ProductOrServiceAxis": {
"auth_ref": [
"r190",
"r312",
"r313",
"r581",
"r627",
"r629"
],
"lang": {
"en-us": {
"role": {
"label": "Product and Service [Axis]",
"terseLabel": "Product and Service [Axis]"
}
}
},
"localname": "ProductOrServiceAxis",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails",
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "stringItemType"
},
"srt_ProductsAndServicesDomain": {
"auth_ref": [
"r190",
"r312",
"r313",
"r581",
"r627",
"r629"
],
"lang": {
"en-us": {
"role": {
"label": "Product and Service [Domain]",
"terseLabel": "Product and Service [Domain]"
}
}
},
"localname": "ProductsAndServicesDomain",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails",
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"srt_RangeAxis": {
"auth_ref": [
"r275",
"r297",
"r347",
"r395",
"r400",
"r573",
"r574",
"r575",
"r576",
"r577",
"r578",
"r580",
"r628",
"r632",
"r666",
"r667"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Axis]",
"terseLabel": "Statistical Measurement [Axis]"
}
}
},
"localname": "RangeAxis",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails",
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "stringItemType"
},
"srt_RangeMember": {
"auth_ref": [
"r275",
"r297",
"r347",
"r395",
"r400",
"r573",
"r574",
"r575",
"r576",
"r577",
"r578",
"r580",
"r628",
"r632",
"r666",
"r667"
],
"lang": {
"en-us": {
"role": {
"label": "Statistical Measurement [Domain]",
"terseLabel": "Statistical Measurement [Domain]"
}
}
},
"localname": "RangeMember",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails",
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "domainItemType"
},
"srt_RepurchaseAgreementCounterpartyNameDomain": {
"auth_ref": [
"r52",
"r53",
"r117",
"r118",
"r276",
"r298"
],
"lang": {
"en-us": {
"role": {
"label": "Counterparty Name [Domain]",
"terseLabel": "Counterparty Name [Domain]"
}
}
},
"localname": "RepurchaseAgreementCounterpartyNameDomain",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/CollaborationsTables",
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "domainItemType"
},
"srt_SegmentGeographicalDomain": {
"auth_ref": [
"r191",
"r192",
"r312",
"r314",
"r630",
"r657",
"r658",
"r659",
"r660",
"r661",
"r662",
"r663",
"r664",
"r665"
],
"lang": {
"en-us": {
"role": {
"label": "Geographical [Domain]",
"terseLabel": "Geographical [Domain]"
}
}
},
"localname": "SegmentGeographicalDomain",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"srt_StatementGeographicalAxis": {
"auth_ref": [
"r191",
"r192",
"r312",
"r314",
"r630",
"r655",
"r657",
"r658",
"r659",
"r660",
"r661",
"r662",
"r663",
"r664",
"r665"
],
"lang": {
"en-us": {
"role": {
"label": "Geographical [Axis]",
"terseLabel": "Geographical [Axis]"
}
}
},
"localname": "StatementGeographicalAxis",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "stringItemType"
},
"srt_WeightedAverageMember": {
"auth_ref": [
"r573",
"r575",
"r578",
"r666",
"r667"
],
"lang": {
"en-us": {
"role": {
"label": "Weighted Average [Member]",
"terseLabel": "Weighted average"
}
}
},
"localname": "WeightedAverageMember",
"nsuri": "http://fasb.org/srt/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
"auth_ref": [
"r38"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
"label": "Accounts Payable and Accrued Liabilities, Current",
"terseLabel": "Accounts payable and accrued liabilities",
"verboseLabel": "AbbVie's payable to Janssen"
}
}
},
"localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
"label": "Accounts Payable and Accrued Liabilities [Member]",
"terseLabel": "Accounts payable and accrued liabilities"
}
}
},
"localname": "AccountsPayableAndAccruedLiabilitiesMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountsReceivableMember": {
"auth_ref": [
"r656"
],
"lang": {
"en-us": {
"role": {
"documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
"label": "Accounts Receivable [Member]",
"terseLabel": "Accounts receivable, net"
}
}
},
"localname": "AccountsReceivableMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountsReceivableNetCurrent": {
"auth_ref": [
"r6",
"r20",
"r196",
"r197"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
"label": "Accounts Receivable, after Allowance for Credit Loss, Current",
"terseLabel": "Accounts receivable, net",
"verboseLabel": "AbbVie's receivable from Janssen"
}
}
},
"localname": "AccountsReceivableNetCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
"auth_ref": [
"r59",
"r65",
"r73",
"r74",
"r75",
"r467"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans including the portion attributable to the noncontrolling interest.",
"label": "Accumulated Defined Benefit Plans Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
"terseLabel": "Pension and post-employment benefits"
}
}
},
"localname": "AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
"auth_ref": [
"r36",
"r229"
],
"calculation": {
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
"order": 2.0,
"parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
"label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
"negatedLabel": "Accumulated depreciation"
}
}
},
"localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
"auth_ref": [
"r56",
"r65",
"r73",
"r74",
"r75",
"r467"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
"label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
"terseLabel": "Foreign currency translation adjustments"
}
}
},
"localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
"auth_ref": [
"r65",
"r73",
"r74",
"r75",
"r466"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
"label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
"terseLabel": "Cash flow hedging activities"
}
}
},
"localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
"terseLabel": "Accumulated Other Comprehensive Income (Loss)"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
"auth_ref": [
"r23",
"r62",
"r64",
"r65",
"r612",
"r637",
"r638"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
"label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
"terseLabel": "Accumulated other comprehensive loss"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
"auth_ref": [
"r73",
"r74",
"r551",
"r552",
"r553",
"r554",
"r555",
"r558"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
"label": "Accumulated Other Comprehensive Income (Loss) [Table]",
"terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeLossTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
"auth_ref": [
"r61",
"r65",
"r73",
"r74",
"r75",
"r120",
"r121",
"r122",
"r467",
"r633",
"r634",
"r675"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
"label": "AOCI Attributable to Parent [Member]",
"terseLabel": "Accumulated other comprehensive loss"
}
}
},
"localname": "AccumulatedOtherComprehensiveIncomeMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
"label": "Additional Financial Information Disclosure [Text Block]",
"terseLabel": "Supplemental Financial Information"
}
}
},
"localname": "AdditionalFinancialInformationDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SupplementalFinancialInformation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_AdditionalPaidInCapitalCommonStock": {
"auth_ref": [
"r21"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
"label": "Additional Paid in Capital, Common Stock",
"terseLabel": "Additional paid-in capital"
}
}
},
"localname": "AdditionalPaidInCapitalCommonStock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
"r120",
"r121",
"r122",
"r415",
"r416",
"r417",
"r514"
],
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid-in Capital [Member]",
"terseLabel": "Additional paid-in capital"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Adjustments to reconcile net earnings to net cash from operating activities:"
}
}
},
"localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AllocatedShareBasedCompensationExpense": {
"auth_ref": [
"r402",
"r411",
"r419"
],
"calculation": {
"http://www.abbvie.com/role/EquityStockBasedCompensationDetails": {
"order": 1.0,
"parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
"label": "Share-based Payment Arrangement, Expense",
"terseLabel": "Pre-tax compensation expense"
}
}
},
"localname": "AllocatedShareBasedCompensationExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockBasedCompensationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
"auth_ref": [
],
"calculation": {
"http://www.abbvie.com/role/EquityStockBasedCompensationDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
"label": "Share-based Payment Arrangement, Expense, after Tax",
"totalLabel": "After-tax compensation expense"
}
}
},
"localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockBasedCompensationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AmortizationOfIntangibleAssets": {
"auth_ref": [
"r106",
"r215",
"r222"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 13.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
"label": "Amortization of Intangible Assets",
"terseLabel": "Amortization of intangible assets",
"verboseLabel": "Amortization expense"
}
}
},
"localname": "AmortizationOfIntangibleAssets",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember": {
"auth_ref": [
"r65",
"r73",
"r74",
"r75",
"r512"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, attributable to parent.",
"label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]",
"terseLabel": "Net investment hedging activities"
}
}
},
"localname": "AociDerivativeQualifyingAsHedgeExcludedComponentParentMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
"auth_ref": [
"r61",
"r65",
"r73",
"r74",
"r75",
"r467"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
"label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
"terseLabel": "Accumulated other comprehensive income (loss)"
}
}
},
"localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
"terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
}
}
},
"localname": "ArrangementsAndNonarrangementTransactionsMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r113",
"r177",
"r181",
"r186",
"r203",
"r261",
"r262",
"r263",
"r264",
"r265",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r461",
"r468",
"r541",
"r566",
"r568",
"r586",
"r609"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets",
"totalLabel": "Total assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets [Abstract]",
"terseLabel": "Assets"
}
}
},
"localname": "AssetsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r7",
"r8",
"r49",
"r113",
"r203",
"r261",
"r262",
"r263",
"r264",
"r265",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r461",
"r468",
"r541",
"r566",
"r568"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Current",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets, Current [Abstract]",
"terseLabel": "Current assets"
}
}
},
"localname": "AssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsFairValueDisclosure": {
"auth_ref": [
"r518"
],
"calculation": {
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Fair Value Disclosure",
"totalLabel": "Total assets"
}
}
},
"localname": "AssetsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsFairValueDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Assets, Fair Value Disclosure [Abstract]",
"terseLabel": "Assets"
}
}
},
"localname": "AssetsFairValueDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
"auth_ref": [
"r199",
"r201",
"r205",
"r593"
],
"calculation": {
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
"order": 2.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
"label": "Debt Securities, Available-for-sale",
"terseLabel": "Debt securities"
}
}
},
"localname": "AvailableForSaleSecuritiesDebtSecurities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AwardTypeAxis": {
"auth_ref": [
"r404",
"r413"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of award under share-based payment arrangement.",
"label": "Award Type [Axis]",
"terseLabel": "Award Type [Axis]"
}
}
},
"localname": "AwardTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
"http://www.abbvie.com/role/EquityStockOptionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_BalanceSheetLocationAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location on balance sheet (statement of financial position).",
"label": "Balance Sheet Location [Axis]",
"terseLabel": "Balance Sheet Location [Axis]"
}
}
},
"localname": "BalanceSheetLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_BalanceSheetLocationDomain": {
"auth_ref": [
"r483",
"r489"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the balance sheet (statement of financial position).",
"label": "Balance Sheet Location [Domain]",
"terseLabel": "Balance Sheet Location [Domain]"
}
}
},
"localname": "BalanceSheetLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
"auth_ref": [
"r105",
"r449"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 8.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
"label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
"terseLabel": "Change in fair value of contingent consideration liabilities"
}
}
},
"localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_BusinessCombinationContingentConsiderationLiability": {
"auth_ref": [
"r446",
"r447",
"r448"
],
"calculation": {
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
"label": "Business Combination, Contingent Consideration, Liability",
"verboseLabel": "Contingent consideration"
}
}
},
"localname": "BusinessCombinationContingentConsiderationLiability",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
"auth_ref": [
"r523"
],
"lang": {
"en-us": {
"role": {
"documentation": "Value of input used to measure contingent consideration liability from business combination.",
"label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
"terseLabel": "Significant unobservable input for contingent consideration"
}
}
},
"localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
],
"xbrltype": "decimalItemType"
},
"us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
"auth_ref": [
"r536",
"r537"
],
"lang": {
"en-us": {
"role": {
"documentation": "Measured as reported on the statement of financial position (balance sheet).",
"label": "Reported Value Measurement [Member]",
"terseLabel": "Book value"
}
}
},
"localname": "CarryingReportedAmountFairValueDisclosureMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r4",
"r33",
"r108"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash and Cash Equivalents, at Carrying Value",
"terseLabel": "Cash and equivalents"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
"auth_ref": [
],
"calculation": {
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
"order": 1.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash and Cash Equivalents, Fair Value Disclosure",
"terseLabel": "Cash and equivalents"
}
}
},
"localname": "CashAndCashEquivalentsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r102",
"r108",
"r110"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
"periodEndLabel": "Cash and equivalents, end of period",
"periodStartLabel": "Cash and equivalents, beginning of period"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"auth_ref": [
"r102",
"r549"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
"totalLabel": "Net change in cash and equivalents"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashFlowHedgingMember": {
"auth_ref": [
"r479"
],
"lang": {
"en-us": {
"role": {
"documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
"label": "Cash Flow Hedging [Member]",
"verboseLabel": "Cash flow hedges"
}
}
},
"localname": "CashFlowHedgingMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ClassOfStockDomain": {
"auth_ref": [
"r111",
"r113",
"r136",
"r140",
"r145",
"r149",
"r151",
"r159",
"r160",
"r161",
"r203",
"r261",
"r265",
"r266",
"r267",
"r270",
"r271",
"r295",
"r296",
"r299",
"r300",
"r541",
"r673"
],
"lang": {
"en-us": {
"role": {
"documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
"label": "Class of Stock [Domain]",
"terseLabel": "Class of Stock [Domain]"
}
}
},
"localname": "ClassOfStockDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "domainItemType"
},
"us-gaap_ClassOfTreasuryStockTable": {
"auth_ref": [
"r307",
"r308",
"r309",
"r310"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
"label": "Class of Treasury Stock [Table]",
"terseLabel": "Class of Treasury Stock [Table]"
}
}
},
"localname": "ClassOfTreasuryStockTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CollaborativeArrangementDisclosureTextBlock": {
"auth_ref": [
"r451",
"r452",
"r455"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
"label": "Collaborative Arrangement Disclosure [Text Block]",
"terseLabel": "Collaborations"
}
}
},
"localname": "CollaborativeArrangementDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/Collaborations"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CollaborativeArrangementMember": {
"auth_ref": [
"r454"
],
"lang": {
"en-us": {
"role": {
"documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
"label": "Collaborative Arrangement [Member]",
"terseLabel": "Collaborative arrangement"
}
}
},
"localname": "CollaborativeArrangementMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
"terseLabel": "Collaborative and license agreements"
}
}
},
"localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/CollaborationsTables",
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CommitmentsAndContingencies": {
"auth_ref": [
"r44",
"r247",
"r595",
"r617"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
"label": "Commitments and Contingencies",
"terseLabel": "Commitments and contingencies"
}
}
},
"localname": "CommitmentsAndContingencies",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Commitments and Contingencies Disclosure [Abstract]",
"terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_CommonStockDividendsPerShareDeclared": {
"auth_ref": [
"r306"
],
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
"label": "Common Stock, Dividends, Per Share, Declared",
"terseLabel": "Cash dividends declared per common share (in dollars per share)"
}
}
},
"localname": "CommonStockDividendsPerShareDeclared",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityCashDividendsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r120",
"r121",
"r514"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock [Member]",
"terseLabel": "Common stock"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r19"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common Stock, Par or Stated Value Per Share",
"terseLabel": "Common stock, par value (in dollars per share)"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r19"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common Stock, Shares Authorized",
"terseLabel": "Common stock, authorized (in shares)"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r19"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common Stock, Shares, Issued",
"terseLabel": "Common stock, issued (in shares)"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValueOutstanding": {
"auth_ref": [
"r19"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
"label": "Common Stock, Value, Outstanding",
"verboseLabel": "Common stock, $0.01 par value, 4,000,000,000 shares authorized, 1,812,622,099 shares issued as of June 30, 2022 and 1,803,195,293 as of December 31, 2021"
}
}
},
"localname": "CommonStockValueOutstanding",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTax": {
"auth_ref": [
"r69",
"r71",
"r72",
"r84",
"r601",
"r623"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
"totalLabel": "Comprehensive income attributable to AbbVie Inc."
}
}
},
"localname": "ComprehensiveIncomeNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
"auth_ref": [
"r69",
"r71",
"r83",
"r459",
"r460",
"r472",
"r600",
"r622"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
"order": 2.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
"terseLabel": "Comprehensive income attributable to noncontrolling interest"
}
}
},
"localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
"auth_ref": [
"r69",
"r71",
"r82",
"r458",
"r472",
"r599",
"r621"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
"label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
"totalLabel": "Comprehensive income"
}
}
},
"localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConcentrationRiskBenchmarkDomain": {
"auth_ref": [
"r165",
"r166",
"r194",
"r538",
"r539",
"r656"
],
"lang": {
"en-us": {
"role": {
"documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
"label": "Concentration Risk Benchmark [Domain]",
"terseLabel": "Concentration Risk Benchmark [Domain]"
}
}
},
"localname": "ConcentrationRiskBenchmarkDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConcentrationRiskByBenchmarkAxis": {
"auth_ref": [
"r165",
"r166",
"r194",
"r538",
"r539",
"r639",
"r656"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by benchmark of concentration risk.",
"label": "Concentration Risk Benchmark [Axis]",
"terseLabel": "Concentration Risk Benchmark [Axis]"
}
}
},
"localname": "ConcentrationRiskByBenchmarkAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskByTypeAxis": {
"auth_ref": [
"r165",
"r166",
"r194",
"r538",
"r539",
"r639",
"r656"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
"label": "Concentration Risk Type [Axis]",
"terseLabel": "Concentration Risk Type [Axis]"
}
}
},
"localname": "ConcentrationRiskByTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Concentration Risk [Line Items]",
"terseLabel": "Concentration of Risk"
}
}
},
"localname": "ConcentrationRiskLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskPercentage1": {
"auth_ref": [
"r165",
"r166",
"r194",
"r538",
"r539"
],
"lang": {
"en-us": {
"role": {
"documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
"label": "Concentration Risk, Percentage",
"terseLabel": "Concentrations risk (as a percent)"
}
}
},
"localname": "ConcentrationRiskPercentage1",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_ConcentrationRiskTable": {
"auth_ref": [
"r162",
"r165",
"r166",
"r167",
"r538",
"r540",
"r656"
],
"lang": {
"en-us": {
"role": {
"documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
"label": "Concentration Risk [Table]",
"terseLabel": "Concentration Risk [Table]"
}
}
},
"localname": "ConcentrationRiskTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConcentrationRiskTypeDomain": {
"auth_ref": [
"r165",
"r166",
"r194",
"r538",
"r539",
"r656"
],
"lang": {
"en-us": {
"role": {
"documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
"label": "Concentration Risk Type [Domain]",
"terseLabel": "Concentration Risk Type [Domain]"
}
}
},
"localname": "ConcentrationRiskTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CostOfGoodsAndServicesSold": {
"auth_ref": [
"r87",
"r581"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": 3.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
},
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
"order": 3.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
"label": "Cost of Goods and Services Sold",
"terseLabel": "Cost of products sold",
"verboseLabel": "Losses (gains) on foreign currency forward exchange contracts"
}
}
},
"localname": "CostOfGoodsAndServicesSold",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CostOfSalesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing cost of sales.",
"label": "Cost of Sales [Member]",
"terseLabel": "Cost of products sold"
}
}
},
"localname": "CostOfSalesMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CostsAndExpenses": {
"auth_ref": [
"r86"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Total costs of sales and operating expenses for the period.",
"label": "Costs and Expenses",
"totalLabel": "Total operating costs and expenses"
}
}
},
"localname": "CostsAndExpenses",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtAndCapitalLeaseObligations": {
"auth_ref": [
"r594",
"r618"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of short-term and long-term debt and lease obligation.",
"label": "Debt and Lease Obligation",
"terseLabel": "Aggregate principal amount outstanding"
}
}
},
"localname": "DebtAndCapitalLeaseObligations",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentAxis": {
"auth_ref": [
"r13",
"r15",
"r16",
"r112",
"r119",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288",
"r291",
"r292",
"r293",
"r294",
"r564",
"r587",
"r588",
"r607"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
"label": "Debt Instrument [Axis]",
"terseLabel": "Debt Instrument [Axis]"
}
}
},
"localname": "DebtInstrumentAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentFaceAmount": {
"auth_ref": [
"r272",
"r291",
"r292",
"r562",
"r564",
"r565"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Face (par) amount of debt instrument at time of issuance.",
"label": "Debt Instrument, Face Amount",
"verboseLabel": "Principal amount of unsecured senior notes"
}
}
},
"localname": "DebtInstrumentFaceAmount",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentInterestRateStatedPercentage": {
"auth_ref": [
"r41",
"r273"
],
"lang": {
"en-us": {
"role": {
"documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
"label": "Debt Instrument, Interest Rate, Stated Percentage",
"terseLabel": "Stated interest rate (as a percent)"
}
}
},
"localname": "DebtInstrumentInterestRateStatedPercentage",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_DebtInstrumentLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Debt Instrument [Line Items]",
"terseLabel": "Debt and Credit Facilities [Line Items]"
}
}
},
"localname": "DebtInstrumentLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentNameDomain": {
"auth_ref": [
"r42",
"r112",
"r119",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288",
"r291",
"r292",
"r293",
"r294",
"r564"
],
"lang": {
"en-us": {
"role": {
"documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
"label": "Debt Instrument, Name [Domain]",
"terseLabel": "Debt Instrument, Name [Domain]"
}
}
},
"localname": "DebtInstrumentNameDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DebtInstrumentTable": {
"auth_ref": [
"r42",
"r112",
"r119",
"r272",
"r273",
"r274",
"r275",
"r276",
"r277",
"r278",
"r279",
"r280",
"r281",
"r282",
"r283",
"r284",
"r285",
"r286",
"r287",
"r288",
"r289",
"r291",
"r292",
"r293",
"r294",
"r302",
"r303",
"r304",
"r305",
"r561",
"r562",
"r564",
"r565",
"r606"
],
"lang": {
"en-us": {
"role": {
"documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Schedule of Long-term Debt Instruments [Table]",
"terseLabel": "Debt and Credit Facilities [Table]"
}
}
},
"localname": "DebtInstrumentTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DebtInstrumentTerm": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Debt Instrument, Term",
"terseLabel": "Term loan credit agreement term"
}
}
},
"localname": "DebtInstrumentTerm",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
"auth_ref": [
"r427"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
"label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
"terseLabel": "Potential change in unrecognized tax benefits"
}
}
},
"localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IncomeTaxesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredIncomeTaxExpenseBenefit": {
"auth_ref": [
"r106",
"r114",
"r430",
"r435",
"r436",
"r437"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
"label": "Deferred Income Tax Expense (Benefit)",
"terseLabel": "Deferred income taxes"
}
}
},
"localname": "DeferredIncomeTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredIncomeTaxLiabilitiesNet": {
"auth_ref": [
"r422",
"r423"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
"label": "Deferred Income Tax Liabilities, Net",
"terseLabel": "Deferred income taxes"
}
}
},
"localname": "DeferredIncomeTaxLiabilitiesNet",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
"auth_ref": [
"r325",
"r363",
"r382",
"r387",
"r388"
],
"calculation": {
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
"order": 5.0,
"parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
"label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
"terseLabel": "Amortization of prior service cost (credit)"
}
}
},
"localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanDisclosureLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Defined Benefit Plan Disclosure [Line Items]",
"terseLabel": "Defined benefit and other post-employment plans"
}
}
},
"localname": "DefinedBenefitPlanDisclosureLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
"auth_ref": [
"r325",
"r361",
"r380",
"r387",
"r388"
],
"calculation": {
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
"order": 3.0,
"parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
"label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
"negatedLabel": "Expected return on plan assets"
}
}
},
"localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanInterestCost": {
"auth_ref": [
"r325",
"r329",
"r360",
"r379",
"r387",
"r388"
],
"calculation": {
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
"order": 4.0,
"parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
"label": "Defined Benefit Plan, Interest Cost",
"terseLabel": "Interest cost"
}
}
},
"localname": "DefinedBenefitPlanInterestCost",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
"auth_ref": [
"r358",
"r377",
"r387",
"r388"
],
"calculation": {
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
"label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
"totalLabel": "Net periodic benefit cost"
}
}
},
"localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DefinedBenefitPlanServiceCost": {
"auth_ref": [
"r327",
"r359",
"r378",
"r387",
"r388"
],
"calculation": {
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails": {
"order": 2.0,
"parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
"label": "Defined Benefit Plan, Service Cost",
"terseLabel": "Service cost"
}
}
},
"localname": "DefinedBenefitPlanServiceCost",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_Depreciation": {
"auth_ref": [
"r106",
"r227"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
"label": "Depreciation",
"terseLabel": "Depreciation",
"verboseLabel": "Depreciation expense"
}
}
},
"localname": "Depreciation",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeContractTypeDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
"label": "Derivative Contract [Domain]",
"terseLabel": "Derivative Contract Type [Domain]"
}
}
},
"localname": "DerivativeContractTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DerivativeFairValueOfDerivativeAsset": {
"auth_ref": [
"r50",
"r53",
"r54",
"r487",
"r579"
],
"calculation": {
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
"order": 5.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
"label": "Derivative Asset, Fair Value, Gross Asset",
"terseLabel": "Foreign currency contracts",
"verboseLabel": "Fair value - Derivatives in asset position"
}
}
},
"localname": "DerivativeFairValueOfDerivativeAsset",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeFairValueOfDerivativeLiability": {
"auth_ref": [
"r50",
"r53",
"r54",
"r487",
"r579"
],
"calculation": {
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
"label": "Derivative Liability, Fair Value, Gross Liability",
"terseLabel": "Foreign currency contracts",
"verboseLabel": "Fair value - Derivatives in liability position"
}
}
},
"localname": "DerivativeFairValueOfDerivativeLiability",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeGainLossOnDerivativeNet": {
"auth_ref": [
"r485"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
"label": "Derivative, Gain (Loss) on Derivative, Net",
"terseLabel": "Derivative instrument net gains (losses) recognized in the consolidate statements of earnings"
}
}
},
"localname": "DerivativeGainLossOnDerivativeNet",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeInstrumentRiskAxis": {
"auth_ref": [
"r53",
"r484",
"r488",
"r496",
"r502"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of derivative contract.",
"label": "Derivative Instrument [Axis]",
"terseLabel": "Derivative Instrument [Axis]"
}
}
},
"localname": "DerivativeInstrumentRiskAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
"auth_ref": [
"r481",
"r484",
"r496"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of hedging relationship.",
"label": "Hedging Relationship [Axis]",
"terseLabel": "Hedging Relationship [Axis]"
}
}
},
"localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
"auth_ref": [
"r481",
"r484",
"r496",
"r502",
"r503",
"r506",
"r509"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
"label": "Derivative Instruments, Gain (Loss) [Table]",
"terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
}
}
},
"localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeInstrumentsGainLossLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Derivative Instruments, Gain (Loss) [Line Items]",
"terseLabel": "Gain (loss) on derivatives"
}
}
},
"localname": "DerivativeInstrumentsGainLossLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeNotionalAmount": {
"auth_ref": [
"r475",
"r477"
],
"lang": {
"en-us": {
"role": {
"documentation": "Nominal or face amount used to calculate payment on derivative.",
"label": "Derivative, Notional Amount",
"terseLabel": "Notional amount of derivative instruments"
}
}
},
"localname": "DerivativeNotionalAmount",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DerivativeTable": {
"auth_ref": [
"r474",
"r476",
"r477",
"r481",
"r482",
"r490",
"r496",
"r504",
"r505",
"r509",
"r513"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
"label": "Derivative [Table]",
"terseLabel": "Derivative [Table]"
}
}
},
"localname": "DerivativeTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DerivativeTermOfContract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Derivative, Term of Contract",
"terseLabel": "Duration of forward exchange contracts"
}
}
},
"localname": "DerivativeTermOfContract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_DerivativesAndFairValueTextBlock": {
"auth_ref": [
"r517",
"r532"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for derivatives and fair value of assets and liabilities.",
"label": "Derivatives and Fair Value [Text Block]",
"terseLabel": "Financial Instruments and Fair Value Measures"
}
}
},
"localname": "DerivativesAndFairValueTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasures"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DerivativesFairValueLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Derivatives, Fair Value [Line Items]",
"terseLabel": "Derivative instruments, notional amount and fair value"
}
}
},
"localname": "DerivativesFairValueLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DesignatedAsHedgingInstrumentMember": {
"auth_ref": [
"r481"
],
"lang": {
"en-us": {
"role": {
"documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
"label": "Designated as Hedging Instrument [Member]",
"terseLabel": "Designated as hedging instrument"
}
}
},
"localname": "DesignatedAsHedgingInstrumentMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DevelopedTechnologyRightsMember": {
"auth_ref": [
"r445"
],
"lang": {
"en-us": {
"role": {
"documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
"label": "Developed Technology Rights [Member]",
"terseLabel": "Developed product rights"
}
}
},
"localname": "DevelopedTechnologyRightsMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_DisaggregationOfRevenueLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Disaggregation of Revenue [Line Items]",
"terseLabel": "Disaggregation of Revenue"
}
}
},
"localname": "DisaggregationOfRevenueLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DisaggregationOfRevenueTable": {
"auth_ref": [
"r312",
"r313",
"r314",
"r315",
"r316",
"r317",
"r318",
"r319"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
"label": "Disaggregation of Revenue [Table]",
"terseLabel": "Disaggregation of Revenue [Table]"
}
}
},
"localname": "DisaggregationOfRevenueTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_DisaggregationOfRevenueTableTextBlock": {
"auth_ref": [
"r312"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
"label": "Disaggregation of Revenue [Table Text Block]",
"terseLabel": "Schedule of worldwide net revenues"
}
}
},
"localname": "DisaggregationOfRevenueTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
"auth_ref": [
"r420"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for share-based payment arrangement.",
"label": "Share-based Payment Arrangement [Text Block]",
"terseLabel": "Equity"
}
}
},
"localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/Equity"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DividendsCommonStockCash": {
"auth_ref": [
"r306"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
"label": "Dividends, Common Stock, Cash",
"negatedTerseLabel": "Dividends declared"
}
}
},
"localname": "DividendsCommonStockCash",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EarningsPerShareAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share [Abstract]",
"terseLabel": "Earnings Per Share [Abstract]"
}
}
},
"localname": "EarningsPerShareAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareBasic": {
"auth_ref": [
"r85",
"r125",
"r126",
"r127",
"r128",
"r129",
"r133",
"r136",
"r149",
"r150",
"r151",
"r155",
"r156",
"r515",
"r516",
"r602",
"r624"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
"label": "Earnings Per Share, Basic",
"terseLabel": "Basic earnings per share (in dollars per share)"
}
}
},
"localname": "EarningsPerShareBasic",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
"http://www.abbvie.com/role/EarningsPerShareDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share, Basic and Diluted [Abstract]",
"terseLabel": "Per share data"
}
}
},
"localname": "EarningsPerShareBasicAndDilutedAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareBasicTwoClassMethodAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share, Basic, Two Class Method [Abstract]",
"terseLabel": "Basic EPS"
}
}
},
"localname": "EarningsPerShareBasicTwoClassMethodAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EarningsPerShareDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareDiluted": {
"auth_ref": [
"r85",
"r125",
"r126",
"r127",
"r128",
"r129",
"r136",
"r149",
"r150",
"r151",
"r155",
"r156",
"r515",
"r516",
"r602",
"r624"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
"label": "Earnings Per Share, Diluted",
"terseLabel": "Diluted earnings per share (in dollars per share)"
}
}
},
"localname": "EarningsPerShareDiluted",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
"http://www.abbvie.com/role/EarningsPerShareDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareDilutedTwoClassMethodAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share, Diluted, Two Class Method [Abstract]",
"terseLabel": "Diluted EPS"
}
}
},
"localname": "EarningsPerShareDilutedTwoClassMethodAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EarningsPerShareDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareTextBlock": {
"auth_ref": [
"r152",
"r153",
"r154",
"r157"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for earnings per share.",
"label": "Earnings Per Share [Text Block]",
"terseLabel": "Earnings Per Share"
}
}
},
"localname": "EarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EarningsPerShare"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
"auth_ref": [
"r549"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 4.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
"label": "Effect of Exchange Rate on Cash and Cash Equivalents",
"terseLabel": "Effect of exchange rate changes on cash and equivalents"
}
}
},
"localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
"auth_ref": [
"r425"
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
"label": "Effective Income Tax Rate Reconciliation, Percent",
"terseLabel": "Effective tax rate"
}
}
},
"localname": "EffectiveIncomeTaxRateContinuingOperations",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IncomeTaxesDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
"auth_ref": [
"r115",
"r425",
"r438"
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
"label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
"terseLabel": "U.S. statutory tax rate"
}
}
},
"localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IncomeTaxesDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
"auth_ref": [
"r412"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
"terseLabel": "Period for recognition of unrecognized compensation cost"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
"http://www.abbvie.com/role/EquityStockOptionsDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
"auth_ref": [
"r412"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
"label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
"terseLabel": "Unrecognized compensation cost"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
"auth_ref": [
"r412"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
"label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
"terseLabel": "Unrecognized compensation cost"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockOptionsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
"auth_ref": [
"r411"
],
"calculation": {
"http://www.abbvie.com/role/EquityStockBasedCompensationDetails": {
"order": 2.0,
"parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
"label": "Share-based Payment Arrangement, Expense, Tax Benefit",
"terseLabel": "Tax benefit"
}
}
},
"localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockBasedCompensationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EmployeeSeveranceMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
"label": "Employee Severance [Member]",
"terseLabel": "Severance and employee benefits"
}
}
},
"localname": "EmployeeSeveranceMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EmployeeStockOptionMember": {
"auth_ref": [
"r409"
],
"lang": {
"en-us": {
"role": {
"documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
"label": "Share-based Payment Arrangement, Option [Member]",
"terseLabel": "Stock Options"
}
}
},
"localname": "EmployeeStockOptionMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockOptionsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquityClassOfTreasuryStockLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Equity, Class of Treasury Stock [Line Items]",
"terseLabel": "Equity, Class of Treasury Stock"
}
}
},
"localname": "EquityClassOfTreasuryStockLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r0",
"r73",
"r74",
"r75",
"r120",
"r121",
"r122",
"r124",
"r130",
"r132",
"r158",
"r204",
"r301",
"r306",
"r415",
"r416",
"r417",
"r431",
"r432",
"r514",
"r551",
"r552",
"r553",
"r554",
"r555",
"r558",
"r633",
"r634",
"r635",
"r675"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]",
"terseLabel": "Equity Component [Domain]"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
"auth_ref": [
"r533"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
"label": "Equity Securities, FV-NI",
"terseLabel": "Equity securities"
}
}
},
"localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
"auth_ref": [
"r202"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investment in equity security without readily determinable fair value.",
"label": "Equity Securities without Readily Determinable Fair Value, Amount",
"terseLabel": "Carrying amount of investments in equity securities that do not have readily determinable fair values"
}
}
},
"localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
"auth_ref": [
"r281",
"r291",
"r292",
"r535"
],
"lang": {
"en-us": {
"role": {
"documentation": "Measured as an estimate of fair value.",
"label": "Estimate of Fair Value Measurement [Member]",
"terseLabel": "Approximate fair value"
}
}
},
"localname": "EstimateOfFairValueFairValueDisclosureMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
"terseLabel": "Fair value, asset and liability measures",
"verboseLabel": "Bases used to measure the approximate fair values of the financial instruments"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
"auth_ref": [
"r518",
"r519",
"r520",
"r529"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
"label": "Fair Value, Recurring and Nonrecurring [Table]",
"terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
"terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
"auth_ref": [
"r521"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
"label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
"terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
"auth_ref": [
"r521"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
"label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
"terseLabel": "Summary of significant level 3 unobservable inputs"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
"auth_ref": [
"r518",
"r536"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
"label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
"terseLabel": "Schedule of book values, approximate fair values and bases used to measure certain financial instruments"
}
}
},
"localname": "FairValueByBalanceSheetGroupingTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueByFairValueHierarchyLevelAxis": {
"auth_ref": [
"r281",
"r291",
"r292",
"r348",
"r349",
"r350",
"r351",
"r352",
"r353",
"r354",
"r387",
"r519",
"r570",
"r571",
"r572"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
"label": "Fair Value Hierarchy and NAV [Axis]",
"terseLabel": "Fair Value Hierarchy and NAV [Axis]"
}
}
},
"localname": "FairValueByFairValueHierarchyLevelAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByMeasurementBasisAxis": {
"auth_ref": [
"r281",
"r291",
"r292",
"r518",
"r530"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by measurement basis.",
"label": "Measurement Basis [Axis]",
"terseLabel": "Measurement Basis [Axis]"
}
}
},
"localname": "FairValueByMeasurementBasisAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByMeasurementFrequencyAxis": {
"auth_ref": [
"r518",
"r519",
"r522",
"r523",
"r531"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by measurement frequency.",
"label": "Measurement Frequency [Axis]",
"terseLabel": "Measurement Frequency [Axis]"
}
}
},
"localname": "FairValueByMeasurementFrequencyAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosureItemAmountsDomain": {
"auth_ref": [
"r281",
"r291",
"r292"
],
"lang": {
"en-us": {
"role": {
"documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
"label": "Fair Value Measurement [Domain]",
"terseLabel": "Fair Value Measurement [Domain]"
}
}
},
"localname": "FairValueDisclosureItemAmountsDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueDisclosuresAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Disclosures [Abstract]",
"terseLabel": "Fair Value Disclosures [Abstract]"
}
}
},
"localname": "FairValueDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_FairValueHedgingMember": {
"auth_ref": [
"r478"
],
"lang": {
"en-us": {
"role": {
"documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
"label": "Fair Value Hedging [Member]",
"terseLabel": "Fair value hedges"
}
}
},
"localname": "FairValueHedgingMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel1Member": {
"auth_ref": [
"r281",
"r348",
"r349",
"r354",
"r387",
"r519",
"r570"
],
"lang": {
"en-us": {
"role": {
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
"label": "Fair Value, Inputs, Level 1 [Member]",
"terseLabel": "Quoted\u00a0prices\u00a0in active markets\u00a0for identical assets (Level\u00a01)"
}
}
},
"localname": "FairValueInputsLevel1Member",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel2Member": {
"auth_ref": [
"r281",
"r291",
"r292",
"r348",
"r349",
"r354",
"r387",
"r519",
"r571"
],
"lang": {
"en-us": {
"role": {
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
"label": "Fair Value, Inputs, Level 2 [Member]",
"terseLabel": "Significant other observable inputs (Level\u00a02)"
}
}
},
"localname": "FairValueInputsLevel2Member",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel3Member": {
"auth_ref": [
"r281",
"r291",
"r292",
"r348",
"r349",
"r350",
"r351",
"r352",
"r353",
"r354",
"r387",
"r519",
"r572"
],
"lang": {
"en-us": {
"role": {
"documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value, Inputs, Level 3 [Member]",
"terseLabel": "Significant unobservable inputs (Level\u00a03)"
}
}
},
"localname": "FairValueInputsLevel3Member",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsQuantitativeInformationAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]",
"terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]"
}
}
},
"localname": "FairValueInputsQuantitativeInformationAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
"terseLabel": "Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)"
}
}
},
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
"auth_ref": [
"r524",
"r529"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
"label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
"terseLabel": "Schedule of changes in fair value of Level 3 inputs"
}
}
},
"localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueMeasurementFrequencyDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Measurement frequency.",
"label": "Measurement Frequency [Domain]",
"terseLabel": "Fair Value Measurement Frequency [Domain]"
}
}
},
"localname": "FairValueMeasurementFrequencyDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
"auth_ref": [
"r527"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.",
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3",
"terseLabel": "Transfers of liabilities into Level 3 of the fair value hierarchy"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
"auth_ref": [
"r527"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.",
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
"terseLabel": "Transfers of liabilities out of Level 3 of the fair value hierarchy"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
"auth_ref": [
"r527"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
"terseLabel": "Transfers of assets into Level 3 of the fair value hierarchy"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net [Abstract]",
"terseLabel": "Transfers of assets or liabilities between the fair value measurement levels"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNetAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
"auth_ref": [
"r527"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
"terseLabel": "Transfers of assets out of Level 3 of the fair value hierarchy"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
"auth_ref": [
"r525"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
"negatedLabel": "Change in fair value recognized in net earnings"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
"auth_ref": [
"r526"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
"negatedTerseLabel": "Payments"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]",
"terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net [Abstract]"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNetAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
"auth_ref": [
"r524"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
"periodEndLabel": "Ending balance",
"periodStartLabel": "Beginning balance"
}
}
},
"localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTransfersofAssetsorLiabilitiesIntoorOutofLevel3oftheFairValueHierarchyDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"auth_ref": [
"r281",
"r291",
"r292",
"r348",
"r349",
"r350",
"r351",
"r352",
"r353",
"r354",
"r387",
"r570",
"r571",
"r572"
],
"lang": {
"en-us": {
"role": {
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
"label": "Fair Value Hierarchy and NAV [Domain]",
"terseLabel": "Fair Value Measurements Fair Value Hierarchy [Domain]"
}
}
},
"localname": "FairValueMeasurementsFairValueHierarchyDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsRecurringMember": {
"auth_ref": [
"r528",
"r531"
],
"lang": {
"en-us": {
"role": {
"documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
"label": "Fair Value, Recurring [Member]",
"terseLabel": "Fair Value, Recurring"
}
}
},
"localname": "FairValueMeasurementsRecurringMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
"auth_ref": [
"r221"
],
"calculation": {
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails": {
"order": 2.0,
"parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Finite-Lived Intangible Assets, Accumulated Amortization",
"negatedLabel": "Accumulated amortization"
}
}
},
"localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
"auth_ref": [
"r216",
"r218",
"r221",
"r224",
"r582",
"r583"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by major type or class of finite-lived intangible assets.",
"label": "Finite-Lived Intangible Assets by Major Class [Axis]",
"terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
}
}
},
"localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsGross": {
"auth_ref": [
"r221",
"r583"
],
"calculation": {
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails": {
"order": 1.0,
"parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Finite-Lived Intangible Assets, Gross",
"terseLabel": "Gross carrying amount"
}
}
},
"localname": "FiniteLivedIntangibleAssetsGross",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Finite-Lived Intangible Assets [Line Items]",
"terseLabel": "Finite-Lived Intangible Assets"
}
}
},
"localname": "FiniteLivedIntangibleAssetsLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
"auth_ref": [
"r216",
"r220"
],
"lang": {
"en-us": {
"role": {
"documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
"label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
"terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
}
}
},
"localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_FiniteLivedIntangibleAssetsNet": {
"auth_ref": [
"r221",
"r582"
],
"calculation": {
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Finite-Lived Intangible Assets, Net",
"totalLabel": "Net carrying amount"
}
}
},
"localname": "FiniteLivedIntangibleAssetsNet",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
"auth_ref": [
"r510"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
"label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
"terseLabel": "Pre-tax gains (losses) to be transferred into cost of products sold for foreign currency cash flow hedges during the next 12 months"
}
}
},
"localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ForeignCurrencyGainLossMember": {
"auth_ref": [
"r501"
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing foreign currency gain (loss).",
"label": "Foreign Currency Gain (Loss) [Member]",
"terseLabel": "Net foreign exchange loss"
}
}
},
"localname": "ForeignCurrencyGainLossMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
"auth_ref": [
"r542",
"r544",
"r546",
"r548"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": 3.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
"label": "Foreign Currency Transaction Gain (Loss), before Tax",
"negatedLabel": "Net foreign exchange loss"
}
}
},
"localname": "ForeignCurrencyTransactionGainLossBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ForeignExchangeContractMember": {
"auth_ref": [
"r53",
"r348",
"r500"
],
"lang": {
"en-us": {
"role": {
"documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
"label": "Foreign Exchange Contract [Member]",
"terseLabel": "Foreign currency contracts"
}
}
},
"localname": "ForeignExchangeContractMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ForeignExchangeForwardMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
"label": "Foreign Exchange Forward [Member]",
"terseLabel": "Foreign currency forward exchange contracts"
}
}
},
"localname": "ForeignExchangeForwardMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet": {
"auth_ref": [
"r495"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net gain (loss) relating to components of the gain (loss) on the cash flow hedging instrument excluded from the assessment of cash flow hedge effectiveness. Recognized in earnings.",
"label": "Gain (Loss) from Components Excluded from Assessment of Cash Flow Hedge Effectiveness, Net",
"terseLabel": "Amount excluded from the assessment of effectiveness for cash flow hedges"
}
}
},
"localname": "GainLossFromComponentsExcludedFromAssessmentOfCashFlowHedgeEffectivenessNet",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet": {
"auth_ref": [
"r494",
"r508"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Net gain (loss) relating to components of the gain (loss) on the fair value hedging instrument excluded from the assessment of fair value hedge effectiveness. Recognized in earnings.",
"label": "Gain (Loss) from Components Excluded from Assessment of Fair Value Hedge Effectiveness, Net",
"terseLabel": "Amount excluded from the assessment of effectiveness for fair value hedges"
}
}
},
"localname": "GainLossFromComponentsExcludedFromAssessmentOfFairValueHedgeEffectivenessNet",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GainLossOnSaleOfOtherAssets": {
"auth_ref": [
"r106"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 14.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of gain (loss) on sale or disposal of other assets.",
"label": "Gain (Loss) on Disposition of Other Assets",
"negatedLabel": "Gain on divestitures",
"verboseLabel": "Pre-tax gain recognized on sale of assets"
}
}
},
"localname": "GainLossOnSaleOfOtherAssets",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GeographicConcentrationRiskMember": {
"auth_ref": [
"r164",
"r656"
],
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
"label": "Geographic Concentration Risk [Member]",
"terseLabel": "Geographic risk"
}
}
},
"localname": "GeographicConcentrationRiskMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_Goodwill": {
"auth_ref": [
"r207",
"r208",
"r568",
"r585"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill",
"periodEndLabel": "Balance at the end of the period",
"periodStartLabel": "Balance at the beginning of the period",
"terseLabel": "Goodwill"
}
}
},
"localname": "Goodwill",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Goodwill and Intangible Assets Disclosure [Abstract]",
"terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
}
}
},
"localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
"auth_ref": [
"r226"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for goodwill and intangible assets.",
"label": "Goodwill and Intangible Assets Disclosure [Text Block]",
"terseLabel": "Goodwill and Intangible Assets"
}
}
},
"localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssets"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
"auth_ref": [
"r209",
"r211"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill, Impaired, Accumulated Impairment Loss",
"terseLabel": "Accumulated goodwill impairment losses"
}
}
},
"localname": "GoodwillImpairedAccumulatedImpairmentLoss",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Goodwill, Impaired, Accumulated Impairment Loss [Abstract]",
"terseLabel": "Accumulated goodwill impairment losses"
}
}
},
"localname": "GoodwillImpairedAccumulatedImpairmentLossAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_GoodwillOtherIncreaseDecrease": {
"auth_ref": [
"r210"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
"label": "Goodwill, Other Increase (Decrease)",
"terseLabel": "Foreign currency translation adjustments"
}
}
},
"localname": "GoodwillOtherIncreaseDecrease",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GoodwillRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Goodwill [Roll Forward]",
"terseLabel": "Changes in the carrying amount of goodwill"
}
}
},
"localname": "GoodwillRollForward",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsGoodwillDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_HedgingDesignationAxis": {
"auth_ref": [
"r481",
"r503"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by designation of purpose of derivative instrument.",
"label": "Hedging Designation [Axis]",
"terseLabel": "Hedging Designation [Axis]"
}
}
},
"localname": "HedgingDesignationAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_HedgingDesignationDomain": {
"auth_ref": [
"r481"
],
"lang": {
"en-us": {
"role": {
"documentation": "Designation of purpose of derivative instrument.",
"label": "Hedging Designation [Domain]",
"terseLabel": "Hedging Designation [Domain]"
}
}
},
"localname": "HedgingDesignationDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_HedgingRelationshipDomain": {
"auth_ref": [
"r481"
],
"lang": {
"en-us": {
"role": {
"documentation": "Nature or intent of a hedge.",
"label": "Hedging Relationship [Domain]",
"terseLabel": "Hedging Relationship [Domain]"
}
}
},
"localname": "HedgingRelationshipDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_InProcessResearchAndDevelopmentMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
"label": "In Process Research and Development [Member]",
"terseLabel": "Acquired IPR&D and milestones"
}
}
},
"localname": "InProcessResearchAndDevelopmentMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
"auth_ref": [
"r79",
"r177",
"r180",
"r182",
"r185",
"r188",
"r584",
"r596",
"r604",
"r625"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": 2.0,
"parentTag": "us-gaap_ProfitLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
"label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
"totalLabel": "Earnings before income tax expense"
}
}
},
"localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncomeStatementAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Income Statement [Abstract]",
"terseLabel": "Income Statement [Abstract]"
}
}
},
"localname": "IncomeStatementAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationAxis": {
"auth_ref": [
"r231",
"r235"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location in the income statement.",
"label": "Income Statement Location [Axis]",
"terseLabel": "Income Statement Location [Axis]"
}
}
},
"localname": "IncomeStatementLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails",
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationDomain": {
"auth_ref": [
"r235"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the income statement.",
"label": "Income Statement Location [Domain]",
"terseLabel": "Income Statement Location [Domain]"
}
}
},
"localname": "IncomeStatementLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails",
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeTaxDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Income Tax Disclosure [Abstract]",
"terseLabel": "Income Tax Disclosure [Abstract]"
}
}
},
"localname": "IncomeTaxDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxDisclosureTextBlock": {
"auth_ref": [
"r115",
"r426",
"r428",
"r429",
"r433",
"r439",
"r441",
"r442",
"r443"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
"label": "Income Tax Disclosure [Text Block]",
"terseLabel": "Income Taxes"
}
}
},
"localname": "IncomeTaxDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IncomeTaxes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_IncomeTaxExpenseBenefit": {
"auth_ref": [
"r116",
"r131",
"r132",
"r176",
"r424",
"r434",
"r440",
"r626"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_ProfitLoss",
"weight": -1.0
},
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
"order": 2.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
"label": "Income Tax Expense (Benefit)",
"terseLabel": "Income tax expense",
"verboseLabel": "Tax expense (benefit)"
}
}
},
"localname": "IncomeTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
"auth_ref": [
"r105"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 11.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
"label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
"terseLabel": "Accounts payable and other liabilities"
}
}
},
"localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsReceivable": {
"auth_ref": [
"r105"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 10.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
"label": "Increase (Decrease) in Accounts Receivable",
"negatedLabel": "Accounts receivable"
}
}
},
"localname": "IncreaseDecreaseInAccountsReceivable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1": {
"auth_ref": [
"r484",
"r491"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of unrealized gain (loss) included in earnings related to the fair value of the hedged item in an interest rate fair value hedge, offset by the gain (loss) on the hedging instrument to the extent that the fair value hedge is determined to be effective.",
"label": "Increase (Decrease) in Fair Value of Hedged Item in Interest Rate Fair Value Hedge",
"terseLabel": "Debt designated as hedged item in fair value hedges gain (loss) recognized in the consolidated statements of earnings"
}
}
},
"localname": "IncreaseDecreaseInFairValueOfHedgedItemInInterestRateFairValueHedge1",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": {
"auth_ref": [
"r105"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.",
"label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable",
"terseLabel": "Income tax assets and liabilities, net"
}
}
},
"localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInInventories": {
"auth_ref": [
"r105"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
"label": "Increase (Decrease) in Inventories",
"negatedLabel": "Inventories"
}
}
},
"localname": "IncreaseDecreaseInInventories",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Increase (Decrease) in Operating Capital [Abstract]",
"terseLabel": "Changes in operating assets and liabilities, net of acquisitions:"
}
}
},
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
"auth_ref": [
"r105"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 15.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
"label": "Increase (Decrease) in Prepaid Expense and Other Assets",
"negatedLabel": "Prepaid expenses and other assets"
}
}
},
"localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
"terseLabel": "Increase (Decrease) in Stockholders' Equity"
}
}
},
"localname": "IncreaseDecreaseInStockholdersEquityRollForward",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
"auth_ref": [
"r137",
"r138",
"r139",
"r151"
],
"calculation": {
"http://www.abbvie.com/role/EarningsPerShareDetails": {
"order": 2.0,
"parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
"label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
"terseLabel": "Effect of dilutive securities (in shares)"
}
}
},
"localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EarningsPerShareDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
"auth_ref": [
"r223"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
"label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
"terseLabel": "Indefinite-lived intangible assets"
}
}
},
"localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
"label": "Intangible Assets, Gross (Excluding Goodwill)",
"terseLabel": "Total intangible assets gross carrying amount"
}
}
},
"localname": "IntangibleAssetsGrossExcludingGoodwill",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IntangibleAssetsNetExcludingGoodwill": {
"auth_ref": [
"r214",
"r219"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
"label": "Intangible Assets, Net (Excluding Goodwill)",
"terseLabel": "Intangible assets, net"
}
}
},
"localname": "IntangibleAssetsNetExcludingGoodwill",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestExpense": {
"auth_ref": [
"r77",
"r175",
"r560",
"r563",
"r603"
],
"calculation": {
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
"order": 1.0,
"parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
"label": "Interest Expense",
"terseLabel": "Interest expense"
}
}
},
"localname": "InterestExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestExpenseMember": {
"auth_ref": [
"r501"
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing interest expense.",
"label": "Interest Expense [Member]",
"terseLabel": "Interest expense, net"
}
}
},
"localname": "InterestExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
"label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
"terseLabel": "Schedule of interest expense, net"
}
}
},
"localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SupplementalFinancialInformationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_InterestIncomeExpenseNonoperatingNet": {
"auth_ref": [
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": 2.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
},
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
"order": 1.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
},
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net amount of nonoperating interest income (expense).",
"label": "Interest Income (Expense), Nonoperating, Net",
"negatedLabel": "Interest expense, net",
"negatedTerseLabel": "Gains on derivative amount excluded from effectiveness testing",
"negatedTotalLabel": "Interest expense, net"
}
}
},
"localname": "InterestIncomeExpenseNonoperatingNet",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": {
"auth_ref": [
"r510"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.",
"label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net",
"terseLabel": "Pre-tax gains (losses) to be transferred into interest expense, net for interest rate swap cash flow hedges during the next 12 months"
}
}
},
"localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestRateDerivativeAssetsAtFairValue": {
"auth_ref": [
],
"calculation": {
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
"order": 4.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.",
"label": "Interest Rate Derivative Assets, at Fair Value",
"terseLabel": "Interest rate swap contracts"
}
}
},
"localname": "InterestRateDerivativeAssetsAtFairValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": {
"auth_ref": [
],
"calculation": {
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.",
"label": "Interest Rate Derivative Liabilities, at Fair Value",
"terseLabel": "Interest rate swap contracts"
}
}
},
"localname": "InterestRateDerivativeLiabilitiesAtFairValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestRateSwapMember": {
"auth_ref": [
"r499"
],
"lang": {
"en-us": {
"role": {
"documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
"label": "Interest Rate Swap [Member]",
"terseLabel": "Interest rate swap contracts",
"verboseLabel": "Designated as fair value hedges"
}
}
},
"localname": "InterestRateSwapMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_InterestRevenueOrExpenseNetAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Interest Revenue (Expense), Net [Abstract]",
"verboseLabel": "Interest Expense, Net"
}
}
},
"localname": "InterestRevenueOrExpenseNetAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_InventoryFinishedGoodsNetOfReserves": {
"auth_ref": [
"r27",
"r206"
],
"calculation": {
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
"order": 1.0,
"parentTag": "us-gaap_InventoryNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
"label": "Inventory, Finished Goods, Net of Reserves",
"terseLabel": "Finished goods"
}
}
},
"localname": "InventoryFinishedGoodsNetOfReserves",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryNet": {
"auth_ref": [
"r5",
"r48",
"r568"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
},
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
"label": "Inventory, Net",
"terseLabel": "Inventories",
"totalLabel": "Inventories"
}
}
},
"localname": "InventoryNet",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryNetAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Inventory, Net [Abstract]",
"terseLabel": "Inventories"
}
}
},
"localname": "InventoryNetAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_InventoryRawMaterialsNetOfReserves": {
"auth_ref": [
"r29",
"r206"
],
"calculation": {
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
"order": 3.0,
"parentTag": "us-gaap_InventoryNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
"label": "Inventory, Raw Materials, Net of Reserves",
"verboseLabel": "Raw materials"
}
}
},
"localname": "InventoryRawMaterialsNetOfReserves",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InventoryWorkInProcessNetOfReserves": {
"auth_ref": [
"r28",
"r206"
],
"calculation": {
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
"order": 2.0,
"parentTag": "us-gaap_InventoryNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
"label": "Inventory, Work in Process, Net of Reserves",
"terseLabel": "Work-in-process"
}
}
},
"localname": "InventoryWorkInProcessNetOfReserves",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentIncomeInterest": {
"auth_ref": [
"r89",
"r174"
],
"calculation": {
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
"order": 2.0,
"parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
"label": "Investment Income, Interest",
"negatedLabel": "Interest income"
}
}
},
"localname": "InvestmentIncomeInterest",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentTypeAxis": {
"auth_ref": [
"r640",
"r641",
"r642",
"r643",
"r644",
"r645",
"r646",
"r647",
"r648",
"r649",
"r650",
"r651",
"r652",
"r653",
"r654"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of investments.",
"label": "Investment Type [Axis]",
"terseLabel": "Investment Type [Axis]"
}
}
},
"localname": "InvestmentTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_InvestmentTypeCategorizationMember": {
"auth_ref": [
"r640",
"r641",
"r642",
"r643",
"r644",
"r645",
"r646",
"r647",
"r648",
"r649",
"r650",
"r651",
"r652",
"r653",
"r654"
],
"lang": {
"en-us": {
"role": {
"documentation": "Asset obtained to generate income or appreciate in value.",
"label": "Investments [Domain]",
"terseLabel": "Investments [Domain]"
}
}
},
"localname": "InvestmentTypeCategorizationMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_InvestmentsFairValueDisclosure": {
"auth_ref": [
"r518"
],
"calculation": {
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
"order": 3.0,
"parentTag": "us-gaap_AssetsFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
"label": "Investments, Fair Value Disclosure",
"terseLabel": "Money market funds and time deposits"
}
}
},
"localname": "InvestmentsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LegalMattersAndContingenciesTextBlock": {
"auth_ref": [
"r257"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
"label": "Legal Matters and Contingencies [Text Block]",
"terseLabel": "Legal Proceedings and Contingencies"
}
}
},
"localname": "LegalMattersAndContingenciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingencies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r26",
"r113",
"r203",
"r541",
"r568",
"r590",
"r615"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "Liabilities and Equity",
"totalLabel": "Total liabilities and equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities and Equity [Abstract]",
"terseLabel": "Liabilities and Equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r40",
"r113",
"r203",
"r261",
"r262",
"r263",
"r265",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r462",
"r468",
"r469",
"r541",
"r566",
"r567",
"r568"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "Liabilities, Current",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrentAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities, Current [Abstract]",
"terseLabel": "Current liabilities"
}
}
},
"localname": "LiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesFairValueDisclosure": {
"auth_ref": [
"r518"
],
"calculation": {
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value of financial and nonfinancial obligations.",
"label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
"totalLabel": "Total liabilities"
}
}
},
"localname": "LiabilitiesFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesFairValueDisclosureAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Liabilities, Fair Value Disclosure [Abstract]",
"terseLabel": "Liabilities"
}
}
},
"localname": "LiabilitiesFairValueDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LicensingAgreementsMember": {
"auth_ref": [
"r444"
],
"lang": {
"en-us": {
"role": {
"documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
"label": "Licensing Agreements [Member]",
"terseLabel": "License agreements"
}
}
},
"localname": "LicensingAgreementsMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_LoansPayableMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Borrowing supported by a written promise to pay an obligation.",
"label": "Loans Payable [Member]",
"terseLabel": "Term loan facilities"
}
}
},
"localname": "LoansPayableMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_LongTermDebt": {
"auth_ref": [
"r16",
"r280",
"r290",
"r291",
"r292",
"r588",
"r611"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
"label": "Long-term Debt",
"terseLabel": "Long-term debt obligations, gross"
}
}
},
"localname": "LongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtAndCapitalLeaseObligations": {
"auth_ref": [
"r16"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
"label": "Long-term Debt and Lease Obligation",
"terseLabel": "Long-term debt and finance lease obligations"
}
}
},
"localname": "LongTermDebtAndCapitalLeaseObligations",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
"auth_ref": [
"r39"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt and lease obligation, classified as current.",
"label": "Long-term Debt and Lease Obligation, Current",
"terseLabel": "Current portion of long-term debt and finance lease obligations"
}
}
},
"localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermInvestments": {
"auth_ref": [
"r34"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
"label": "Long-term Investments",
"terseLabel": "Investments"
}
}
},
"localname": "LongTermInvestments",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongtermDebtTypeAxis": {
"auth_ref": [
"r42"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of long-term debt.",
"label": "Long-term Debt, Type [Axis]",
"terseLabel": "Long-term Debt, Type [Axis]"
}
}
},
"localname": "LongtermDebtTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LongtermDebtTypeDomain": {
"auth_ref": [
"r42",
"r260"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
"label": "Long-term Debt, Type [Domain]",
"terseLabel": "Long-term Debt, Type [Domain]"
}
}
},
"localname": "LongtermDebtTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_LossContingenciesLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Loss Contingencies [Line Items]",
"terseLabel": "Legal Proceedings and Contingencies"
}
}
},
"localname": "LossContingenciesLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LossContingenciesTable": {
"auth_ref": [
"r247",
"r248",
"r249",
"r252",
"r253",
"r254",
"r256",
"r258",
"r259"
],
"lang": {
"en-us": {
"role": {
"documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
"label": "Loss Contingencies [Table]",
"terseLabel": "Loss Contingencies [Table]"
}
}
},
"localname": "LossContingenciesTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LossContingencyClaimsDismissedNumber": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of claims dismissed.",
"label": "Loss Contingency, Claims Dismissed, Number",
"terseLabel": "Number of plaintiff claims dismissed"
}
}
},
"localname": "LossContingencyClaimsDismissedNumber",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "integerItemType"
},
"us-gaap_LossContingencyEstimateOfPossibleLoss": {
"auth_ref": [
"r251",
"r255",
"r258"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
"label": "Loss Contingency, Estimate of Possible Loss",
"terseLabel": "Litigation charge related to potential settlement"
}
}
},
"localname": "LossContingencyEstimateOfPossibleLoss",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LossContingencyNewClaimsFiledNumber": {
"auth_ref": [
"r250"
],
"lang": {
"en-us": {
"role": {
"documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
"label": "Loss Contingency, New Claims Filed, Number",
"terseLabel": "Number of parties to lawsuit (in investment funds)"
}
}
},
"localname": "LossContingencyNewClaimsFiledNumber",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "integerItemType"
},
"us-gaap_LossContingencyNumberOfPlaintiffs": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
"label": "Loss Contingency, Number of Plaintiffs",
"terseLabel": "Number of healthcare benefit providers acting as plaintiff in lawsuit"
}
}
},
"localname": "LossContingencyNumberOfPlaintiffs",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "integerItemType"
},
"us-gaap_LossContingencyPendingClaimsNumber": {
"auth_ref": [
"r250"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of pending claims pertaining to a loss contingency.",
"label": "Loss Contingency, Pending Claims, Number",
"terseLabel": "Number of claims pending"
}
}
},
"localname": "LossContingencyPendingClaimsNumber",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "integerItemType"
},
"us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1": {
"auth_ref": [
"r511"
],
"lang": {
"en-us": {
"role": {
"documentation": "Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Maximum Length of Time Hedged in Cash Flow Hedge",
"terseLabel": "Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold"
}
}
},
"localname": "MaximumLengthOfTimeHedgedInCashFlowHedge1",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_MeasurementInputDiscountRateMember": {
"auth_ref": [
"r521"
],
"lang": {
"en-us": {
"role": {
"documentation": "Measurement input using interest rate to determine present value of future cash flows.",
"label": "Measurement Input, Discount Rate [Member]",
"terseLabel": "Discount rate"
}
}
},
"localname": "MeasurementInputDiscountRateMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_MeasurementInputTypeAxis": {
"auth_ref": [
"r521"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of measurement input used to determine value of asset and liability.",
"label": "Measurement Input Type [Axis]",
"terseLabel": "Measurement Input Type [Axis]"
}
}
},
"localname": "MeasurementInputTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_MeasurementInputTypeDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Measurement input used to determine value of asset and liability.",
"label": "Measurement Input Type [Domain]",
"terseLabel": "Measurement Input Type [Domain]"
}
}
},
"localname": "MeasurementInputTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresSignificantLevel3UnobservableInputsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_MinorityInterest": {
"auth_ref": [
"r47",
"r113",
"r203",
"r261",
"r265",
"r266",
"r267",
"r270",
"r271",
"r541",
"r589",
"r614"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
"label": "Stockholders' Equity Attributable to Noncontrolling Interest",
"terseLabel": "Noncontrolling interest"
}
}
},
"localname": "MinorityInterest",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_MinorityInterestPeriodIncreaseDecrease": {
"auth_ref": [
"r457"
],
"lang": {
"en-us": {
"role": {
"documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.",
"label": "Noncontrolling Interest, Period Increase (Decrease)",
"terseLabel": "Change in noncontrolling interest"
}
}
},
"localname": "MinorityInterestPeriodIncreaseDecrease",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_MoneyMarketFundsMember": {
"auth_ref": [
"r348"
],
"lang": {
"en-us": {
"role": {
"documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
"label": "Money Market Funds [Member]",
"terseLabel": "Money market funds and time deposits"
}
}
},
"localname": "MoneyMarketFundsMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFairValueMeasuresDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r102"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 3.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "Net Cash Provided by (Used in) Financing Activities",
"totalLabel": "Cash flows from financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
"terseLabel": "Cash flows from financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r102"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "Net Cash Provided by (Used in) Investing Activities",
"totalLabel": "Cash flows from investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
"terseLabel": "Cash flows from investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r102",
"r104",
"r107"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "Net Cash Provided by (Used in) Operating Activities",
"totalLabel": "Cash flows from operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
"terseLabel": "Cash flows from operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetIncomeLoss": {
"auth_ref": [
"r2",
"r67",
"r70",
"r75",
"r80",
"r107",
"r113",
"r123",
"r125",
"r126",
"r127",
"r128",
"r131",
"r132",
"r147",
"r177",
"r180",
"r182",
"r185",
"r188",
"r203",
"r261",
"r262",
"r263",
"r265",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r516",
"r541",
"r597",
"r619"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
},
"http://www.abbvie.com/role/EarningsPerShareDetails": {
"order": 1.0,
"parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
"weight": 1.0
},
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
"label": "Net Income (Loss) Attributable to Parent",
"negatedTotalLabel": "Total reclassifications, net of tax",
"terseLabel": "Net earnings attributable to AbbVie Inc.",
"totalLabel": "Net earnings attributable to AbbVie Inc."
}
}
},
"localname": "NetIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
"http://www.abbvie.com/role/EarningsPerShareDetails",
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
"auth_ref": [
"r67",
"r70",
"r75",
"r131",
"r132",
"r464",
"r471"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": 2.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
"label": "Net Income (Loss) Attributable to Noncontrolling Interest",
"terseLabel": "Net earnings attributable to noncontrolling interest"
}
}
},
"localname": "NetIncomeLossAttributableToNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
"auth_ref": [
"r125",
"r126",
"r127",
"r128",
"r133",
"r134",
"r148",
"r151",
"r177",
"r180",
"r182",
"r185",
"r188"
],
"calculation": {
"http://www.abbvie.com/role/EarningsPerShareDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
"label": "Net Income (Loss) Available to Common Stockholders, Basic",
"totalLabel": "Earnings available to common shareholders"
}
}
},
"localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EarningsPerShareDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
"auth_ref": [
"r135",
"r141",
"r142",
"r143",
"r144",
"r148",
"r151"
],
"calculation": {
"http://www.abbvie.com/role/EarningsPerShareDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
"label": "Net Income (Loss) Available to Common Stockholders, Diluted",
"totalLabel": "Earnings available to common shareholders"
}
}
},
"localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EarningsPerShareDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetInvestmentHedgingMember": {
"auth_ref": [
"r480"
],
"lang": {
"en-us": {
"role": {
"documentation": "Hedges of a net investment in a foreign operation.",
"label": "Net Investment Hedging [Member]",
"terseLabel": "Net investment hedges"
}
}
},
"localname": "NetInvestmentHedgingMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_NonUsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Countries excluding the United States of America (US).",
"label": "Non-US [Member]",
"terseLabel": "International"
}
}
},
"localname": "NonUsMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_NoncontrollingInterestMember": {
"auth_ref": [
"r120",
"r121",
"r122",
"r306",
"r456"
],
"lang": {
"en-us": {
"role": {
"documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
"label": "Noncontrolling Interest [Member]",
"terseLabel": "Noncontrolling interest"
}
}
},
"localname": "NoncontrollingInterestMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_NondesignatedMember": {
"auth_ref": [
"r481"
],
"lang": {
"en-us": {
"role": {
"documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
"label": "Not Designated as Hedging Instrument [Member]",
"terseLabel": "Not designated as hedging instrument",
"verboseLabel": "Not designated as hedges"
}
}
},
"localname": "NondesignatedMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_NumberOfOperatingSegments": {
"auth_ref": [
"r169"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
"label": "Number of Operating Segments",
"terseLabel": "Number of operating segments"
}
}
},
"localname": "NumberOfOperatingSegments",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationAdditionalInformationDetails"
],
"xbrltype": "integerItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
"r177",
"r180",
"r182",
"r185",
"r188"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "Operating Income (Loss)",
"totalLabel": "Operating earnings"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
"terseLabel": "Basis of Presentation"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
"auth_ref": [
"r3",
"r473"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
"label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
"terseLabel": "Basis of Presentation"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/BasisofPresentation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_OtherAssetsNoncurrent": {
"auth_ref": [
"r37"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 6.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncurrent assets classified as other.",
"label": "Other Assets, Noncurrent",
"terseLabel": "Other assets"
}
}
},
"localname": "OtherAssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
"auth_ref": [
"r57",
"r62",
"r543",
"r545",
"r550"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
"label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
"terseLabel": "Foreign currency translation adjustments, net of tax expense (benefit) of $(12) for the three months and $(19) for the six months ended June 30, 2022 and $1 for the three months and $(24) for the six months ended June 30, 2021"
}
}
},
"localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
"auth_ref": [
"r65",
"r73",
"r74",
"r76",
"r551",
"r553",
"r558"
],
"calculation": {
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails": {
"order": 1.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
"label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
"terseLabel": "Other comprehensive income (loss) before reclassifications"
}
}
},
"localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
"auth_ref": [
"r58",
"r62"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
"order": 2.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
"label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
"terseLabel": "Cash flow hedging activities, net of tax expense (benefit) of $5 for the three months and $3 for the six months ended June 30, 2022 and $\u2014 for the three months and $3 for the six months ended June 30, 2021"
}
}
},
"localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
"auth_ref": [
"r63"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
"label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
"terseLabel": "Cash flow hedging activities, tax expense (benefit)"
}
}
},
"localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
"auth_ref": [
"r58",
"r62",
"r486",
"r492",
"r507"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
"label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
"terseLabel": "Pre-tax gains (losses) from cash flow hedges recognized in other comprehensive income"
}
}
},
"localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
"auth_ref": [
"r55",
"r63",
"r547",
"r557"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
"label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
"terseLabel": "Foreign currency translation adjustments, tax expense (benefit)"
}
}
},
"localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
"auth_ref": [
"r497"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
"label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
"terseLabel": "Pre-tax gains (losses) from net investment hedge instruments recognized in other comprehensive income"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
"auth_ref": [
"r68",
"r71",
"r73",
"r74",
"r76",
"r81",
"r301",
"r551",
"r556",
"r558",
"r598",
"r620"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
"order": 2.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
},
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
"label": "Other Comprehensive Income (Loss), Net of Tax",
"terseLabel": "Other comprehensive income (loss), net of tax",
"totalLabel": "Other comprehensive income (loss)"
}
}
},
"localname": "OtherComprehensiveIncomeLossNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
"auth_ref": [
"r60",
"r62"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
"order": 3.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
"label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
"negatedLabel": "Pension and post-employment benefits, net of tax expense (benefit) of $11 for the three months and $21 for the six months ended June 30, 2022 and $14 for the three months and $33 for the six months ended June 30, 2021"
}
}
},
"localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
"auth_ref": [
"r60",
"r63",
"r458"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
"label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
"negatedLabel": "Pension and post-employment benefits, tax expense (benefit)"
}
}
},
"localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]",
"terseLabel": "Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]"
}
}
},
"localname": "OtherComprehensiveIncomeLossTaxParentheticalDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParentheticalUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_OtherLiabilitiesMember": {
"auth_ref": [
"r483",
"r506"
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing other liabilities.",
"label": "Other Liabilities [Member]",
"terseLabel": "Other long-term liabilities"
}
}
},
"localname": "OtherLiabilitiesMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_OtherLiabilitiesNoncurrent": {
"auth_ref": [
"r43"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
"label": "Other Liabilities, Noncurrent",
"terseLabel": "Other long-term liabilities"
}
}
},
"localname": "OtherLiabilitiesNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNoncashIncomeExpense": {
"auth_ref": [
"r107"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 7.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
"label": "Other Noncash Income (Expense)",
"negatedLabel": "Other, net"
}
}
},
"localname": "OtherNoncashIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherNoncurrentAssetsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing other noncurrent assets.",
"label": "Other Noncurrent Assets [Member]",
"terseLabel": "Other assets"
}
}
},
"localname": "OtherNoncurrentAssetsMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_OtherNonoperatingIncomeExpense": {
"auth_ref": [
"r90"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": 4.0,
"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
"label": "Other Nonoperating Income (Expense)",
"negatedLabel": "Other expense, net"
}
}
},
"localname": "OtherNonoperatingIncomeExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherOperatingIncomeExpenseMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing other operating income (expense).",
"label": "Other Operating Income (Expense) [Member]",
"terseLabel": "Other operating income (expense)"
}
}
},
"localname": "OtherOperatingIncomeExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_OtherOperatingIncomeExpenseNet": {
"auth_ref": [
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": 5.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
"label": "Other Operating Income (Expense), Net",
"terseLabel": "Other operating income"
}
}
},
"localname": "OtherOperatingIncomeExpenseNet",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
"auth_ref": [
"r321",
"r324",
"r326",
"r327",
"r328",
"r329",
"r330",
"r331",
"r332",
"r333",
"r334",
"r335",
"r336",
"r337",
"r338",
"r339",
"r340",
"r341",
"r342",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r349",
"r350",
"r351",
"r352",
"r353",
"r354",
"r356",
"r357",
"r358",
"r359",
"r360",
"r361",
"r362",
"r363",
"r364",
"r365",
"r366",
"r367",
"r368",
"r369",
"r370",
"r371",
"r372",
"r374",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r383",
"r384",
"r385",
"r386",
"r387",
"r388",
"r389",
"r390",
"r391",
"r392",
"r393",
"r394"
],
"lang": {
"en-us": {
"role": {
"documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
"label": "Other Postretirement Benefits Plan [Member]",
"terseLabel": "Other post-employment plans"
}
}
},
"localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_OtherRestructuringMember": {
"auth_ref": [
"r233",
"r234",
"r242",
"r243"
],
"lang": {
"en-us": {
"role": {
"documentation": "Restructuring and related activities classified as other.",
"label": "Other Restructuring [Member]",
"terseLabel": "Other integration"
}
}
},
"localname": "OtherRestructuringMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic": {
"auth_ref": [
"r146",
"r148"
],
"calculation": {
"http://www.abbvie.com/role/EarningsPerShareDetails": {
"order": 2.0,
"parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.",
"label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Basic",
"terseLabel": "Earnings allocated to participating securities"
}
}
},
"localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EarningsPerShareDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted": {
"auth_ref": [
"r148"
],
"calculation": {
"http://www.abbvie.com/role/EarningsPerShareDetails": {
"order": 2.0,
"parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of earnings (loss) distributed and earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.",
"label": "Participating Securities, Distributed and Undistributed Earnings (Loss), Diluted",
"terseLabel": "Earnings allocated to participating securities"
}
}
},
"localname": "ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EarningsPerShareDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
"auth_ref": [
"r99"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
"label": "Payment for Contingent Consideration Liability, Financing Activities",
"negatedTerseLabel": "Payments of contingent consideration liabilities"
}
}
},
"localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
"auth_ref": [
"r91",
"r93"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
"label": "Payments for (Proceeds from) Other Investing Activities",
"negatedTerseLabel": "Other, net"
}
}
},
"localname": "PaymentsForProceedsFromOtherInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsForRepurchaseOfCommonStock": {
"auth_ref": [
"r97"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow to reacquire common stock during the period.",
"label": "Payments for Repurchase of Common Stock",
"negatedLabel": "Purchases of treasury stock"
}
}
},
"localname": "PaymentsForRepurchaseOfCommonStock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsOfDividends": {
"auth_ref": [
"r97"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
"label": "Payments of Dividends",
"negatedLabel": "Dividends paid"
}
}
},
"localname": "PaymentsOfDividends",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquireMarketableSecurities": {
"auth_ref": [
"r200"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow for purchase of marketable security.",
"label": "Payments to Acquire Marketable Securities",
"negatedLabel": "Purchases of investment securities"
}
}
},
"localname": "PaymentsToAcquireMarketableSecurities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquireOtherInvestments": {
"auth_ref": [
"r93"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow to acquire investments classified as other.",
"label": "Payments to Acquire Other Investments",
"negatedLabel": "Acquisitions and investments",
"negatedTerseLabel": "Cash outflows related to acquisitions and investments"
}
}
},
"localname": "PaymentsToAcquireOtherInvestments",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
"auth_ref": [
"r92"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
"label": "Payments to Acquire Property, Plant, and Equipment",
"negatedLabel": "Acquisitions of property and equipment"
}
}
},
"localname": "PaymentsToAcquirePropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PensionPlansDefinedBenefitMember": {
"auth_ref": [
"r320",
"r324",
"r326",
"r327",
"r328",
"r329",
"r330",
"r331",
"r332",
"r333",
"r334",
"r335",
"r336",
"r337",
"r338",
"r339",
"r340",
"r341",
"r342",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r349",
"r350",
"r351",
"r352",
"r353",
"r354",
"r355",
"r356",
"r357",
"r358",
"r359",
"r360",
"r361",
"r362",
"r363",
"r364",
"r365",
"r366",
"r367",
"r368",
"r369",
"r370",
"r371",
"r372",
"r374",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r383",
"r384",
"r385",
"r386",
"r387",
"r388",
"r389",
"r390",
"r396",
"r397",
"r398",
"r399"
],
"lang": {
"en-us": {
"role": {
"documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
"label": "Pension Plan [Member]",
"terseLabel": "Defined benefit plans"
}
}
},
"localname": "PensionPlansDefinedBenefitMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PortionAtFairValueFairValueDisclosureMember": {
"auth_ref": [
"r534"
],
"lang": {
"en-us": {
"role": {
"documentation": "Measured at fair value for financial reporting purposes.",
"label": "Portion at Fair Value Measurement [Member]",
"terseLabel": "Portion at fair value measurement"
}
}
},
"localname": "PortionAtFairValueFairValueDisclosureMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_PostemploymentBenefitsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Postemployment Benefits [Abstract]",
"terseLabel": "Postemployment Benefits [Abstract]"
}
}
},
"localname": "PostemploymentBenefitsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_PostemploymentBenefitsDisclosureTextBlock": {
"auth_ref": [
"r322",
"r323"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for postemployment benefits, which may include supplemental unemployment benefits, obligations recognized for all types of benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement. Disclosure may also include discussion that an obligation for postemployment benefits is not accrued in accordance with regulation only because the amount cannot be reasonably estimated.",
"label": "Postemployment Benefits Disclosure [Text Block]",
"terseLabel": "Post-Employment Benefits"
}
}
},
"localname": "PostemploymentBenefitsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/PostEmploymentBenefits"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_PrepaidExpenseAndOtherAssets": {
"auth_ref": [
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 5.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
"label": "Prepaid Expense and Other Assets",
"terseLabel": "Prepaid expenses and other"
}
}
},
"localname": "PrepaidExpenseAndOtherAssets",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
"label": "Prepaid Expenses and Other Current Assets [Member]",
"terseLabel": "Prepaid expenses and other"
}
}
},
"localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
"auth_ref": [
"r95"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
"label": "Proceeds from Issuance of Long-term Debt",
"terseLabel": "Proceeds from issuance of long-term debt"
}
}
},
"localname": "ProceedsFromIssuanceOfLongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
"auth_ref": [
"r96",
"r100"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
"label": "Proceeds from (Payments for) Other Financing Activities",
"terseLabel": "Other, net"
}
}
},
"localname": "ProceedsFromPaymentsForOtherFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities": {
"auth_ref": [
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from long-term debt, including capital lease obligations and mandatory redeemable capital securities.",
"label": "Proceeds from (Repayments of) Long-term Debt and Capital Securities",
"negatedTerseLabel": "Repayments of long-term debt"
}
}
},
"localname": "ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
"auth_ref": [
"r91"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
"label": "Proceeds from Sale, Maturity and Collection of Investments",
"terseLabel": "Sales and maturities of investment securities"
}
}
},
"localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromSaleOfOtherAssets1": {
"auth_ref": [
"r103"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow from the sale of other assets as part of operating activities.",
"label": "Proceeds from Sale of Other Assets",
"terseLabel": "Proceeds from sale of assets"
}
}
},
"localname": "ProceedsFromSaleOfOtherAssets1",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromStockOptionsExercised": {
"auth_ref": [
"r94",
"r414"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 7.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
"label": "Proceeds from Stock Options Exercised",
"terseLabel": "Proceeds from the exercise of stock options"
}
}
},
"localname": "ProceedsFromStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProductConcentrationRiskMember": {
"auth_ref": [
"r163"
],
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
"label": "Product Concentration Risk [Member]",
"terseLabel": "HUMIRA"
}
}
},
"localname": "ProductConcentrationRiskMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ProfitLoss": {
"auth_ref": [
"r2",
"r67",
"r70",
"r75",
"r101",
"r113",
"r123",
"r131",
"r132",
"r177",
"r180",
"r182",
"r185",
"r188",
"r203",
"r261",
"r262",
"r263",
"r265",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r458",
"r463",
"r465",
"r471",
"r472",
"r516",
"r541",
"r604"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
},
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
"label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
"terseLabel": "Net earnings",
"totalLabel": "Net earnings",
"verboseLabel": "Net earnings"
}
}
},
"localname": "ProfitLoss",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentGross": {
"auth_ref": [
"r35",
"r228"
],
"calculation": {
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
"order": 1.0,
"parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Gross",
"terseLabel": "Property and equipment, gross"
}
}
},
"localname": "PropertyPlantAndEquipmentGross",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentNet": {
"auth_ref": [
"r10",
"r11",
"r230",
"r568",
"r605",
"r616"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
},
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Net",
"terseLabel": "Property and equipment, net",
"totalLabel": "Property and equipment, net"
}
}
},
"localname": "PropertyPlantAndEquipmentNet",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentNetAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Property, Plant and Equipment, Net [Abstract]",
"terseLabel": "Property and Equipment"
}
}
},
"localname": "PropertyPlantAndEquipmentNetAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SupplementalFinancialInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_PropertyPlantAndEquipmentTextBlock": {
"auth_ref": [
"r10",
"r230"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
"label": "Property, Plant and Equipment [Table Text Block]",
"terseLabel": "Schedule of property and equipment, net"
}
}
},
"localname": "PropertyPlantAndEquipmentTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SupplementalFinancialInformationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
"terseLabel": "Significant amounts reclassified out of each component of AOCI"
}
}
},
"localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": {
"auth_ref": [
"r65",
"r73",
"r74",
"r551",
"r555",
"r558"
],
"calculation": {
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
"order": 2.0,
"parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).",
"label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax",
"negatedTerseLabel": "Amortization of actuarial losses and other"
}
}
},
"localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
"auth_ref": [
"r65",
"r73",
"r74",
"r76",
"r551",
"r555",
"r558"
],
"calculation": {
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails": {
"order": 2.0,
"parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
"weight": -1.0
},
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
"label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
"negatedLabel": "Net losses (gains) reclassified from accumulated other comprehensive loss",
"negatedTotalLabel": "Total reclassifications, net of tax"
}
}
},
"localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
"terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax"
}
}
},
"localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ReclassificationFromAociCurrentPeriodTax": {
"auth_ref": [
"r63",
"r66",
"r73"
],
"calculation": {
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails": {
"order": 1.0,
"parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).",
"label": "Reclassification from AOCI, Current Period, Tax",
"terseLabel": "Tax benefit"
}
}
},
"localname": "ReclassificationFromAociCurrentPeriodTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
"auth_ref": [
"r75"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
"label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
"terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
}
}
},
"localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
"auth_ref": [
"r75"
],
"lang": {
"en-us": {
"role": {
"documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
"label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
"terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
}
}
},
"localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
"auth_ref": [
"r75"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
"label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
"terseLabel": "Reclassification out of accumulated other comprehensive loss"
}
}
},
"localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
"auth_ref": [
"r75"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
"label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
"terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
}
}
},
"localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
"label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
"terseLabel": "Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss"
}
}
},
"localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": {
"auth_ref": [
"r98"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.",
"label": "Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security",
"negatedTerseLabel": "Repayments of long-term debt and finance lease obligations"
}
}
},
"localname": "RepaymentsOfLongTermDebtAndCapitalSecurities",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
"auth_ref": [
"r217"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
"label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
"terseLabel": "Acquired IPR&D and milestones"
}
}
},
"localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
"auth_ref": [
"r421"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": 2.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
"label": "Research and Development Expense (Excluding Acquired in Process Cost)",
"terseLabel": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpenseMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
"label": "Research and Development Expense [Member]",
"terseLabel": "Research and development"
}
}
},
"localname": "ResearchAndDevelopmentExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestructuringAndRelatedActivitiesAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Restructuring and Related Activities [Abstract]",
"terseLabel": "Restructuring and Related Activities [Abstract]"
}
}
},
"localname": "RestructuringAndRelatedActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
"auth_ref": [
"r232",
"r234",
"r237",
"r245",
"r246"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
"label": "Restructuring and Related Activities Disclosure [Text Block]",
"terseLabel": "Integration and Restructuring Plans"
}
}
},
"localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlans"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RestructuringAndRelatedCostExpectedCost1": {
"auth_ref": [
"r233",
"r236",
"r242",
"r244"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
"label": "Restructuring and Related Cost, Expected Cost",
"terseLabel": "Integration related costs"
}
}
},
"localname": "RestructuringAndRelatedCostExpectedCost1",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestructuringAndRelatedCostIncurredCost": {
"auth_ref": [
"r233",
"r236",
"r242",
"r244"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
"label": "Restructuring and Related Cost, Incurred Cost",
"terseLabel": "Charges associated with integration or restructuring plans"
}
}
},
"localname": "RestructuringAndRelatedCostIncurredCost",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestructuringCostAndReserveAxis": {
"auth_ref": [
"r233",
"r234",
"r242",
"r243"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of restructuring cost.",
"label": "Restructuring Type [Axis]",
"terseLabel": "Restructuring Type [Axis]"
}
}
},
"localname": "RestructuringCostAndReserveAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RestructuringCostAndReserveLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Restructuring Cost and Reserve [Line Items]",
"terseLabel": "Restructuring charges"
}
}
},
"localname": "RestructuringCostAndReserveLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
"http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_RestructuringPlanAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by individual restructuring plan.",
"label": "Restructuring Plan [Axis]",
"terseLabel": "Restructuring Plan [Axis]"
}
}
},
"localname": "RestructuringPlanAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
"http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_RestructuringPlanDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Identification of the individual restructuring plans.",
"label": "Restructuring Plan [Domain]",
"terseLabel": "Restructuring Plan [Domain]"
}
}
},
"localname": "RestructuringPlanDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
"http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestructuringReserve": {
"auth_ref": [
"r234",
"r240"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
"label": "Restructuring Reserve",
"periodEndLabel": "Accrued balance end of the period",
"periodStartLabel": "Accrued balance beginning of the period"
}
}
},
"localname": "RestructuringReserve",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RestructuringReserveRollForward": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
"label": "Restructuring Reserve [Roll Forward]",
"terseLabel": "Restructuring reserve rollforward"
}
}
},
"localname": "RestructuringReserveRollForward",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r22",
"r306",
"r418",
"r568",
"r613",
"r636",
"r638"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings (Accumulated Deficit)",
"terseLabel": "Retained earnings"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r0",
"r120",
"r121",
"r122",
"r124",
"r130",
"r132",
"r204",
"r415",
"r416",
"r417",
"r431",
"r432",
"r514",
"r633",
"r635"
],
"lang": {
"en-us": {
"role": {
"documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
"label": "Retained Earnings [Member]",
"terseLabel": "Retained earnings"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_RetirementPlanTypeAxis": {
"auth_ref": [
"r320",
"r321",
"r324",
"r326",
"r327",
"r328",
"r329",
"r330",
"r331",
"r332",
"r333",
"r334",
"r335",
"r336",
"r337",
"r338",
"r339",
"r340",
"r341",
"r342",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r349",
"r350",
"r351",
"r352",
"r353",
"r354",
"r355",
"r356",
"r357",
"r358",
"r359",
"r360",
"r361",
"r362",
"r363",
"r364",
"r365",
"r366",
"r367",
"r368",
"r369",
"r370",
"r371",
"r372",
"r374",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r383",
"r384",
"r385",
"r386",
"r387",
"r388",
"r389",
"r390",
"r391",
"r392",
"r393",
"r394",
"r396",
"r397",
"r398",
"r399"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
"label": "Retirement Plan Type [Axis]",
"terseLabel": "Retirement Plan Type [Axis]"
}
}
},
"localname": "RetirementPlanTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_RetirementPlanTypeDomain": {
"auth_ref": [
"r320",
"r321",
"r324",
"r326",
"r327",
"r328",
"r329",
"r330",
"r331",
"r332",
"r333",
"r334",
"r335",
"r336",
"r337",
"r338",
"r339",
"r340",
"r341",
"r342",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r349",
"r350",
"r351",
"r352",
"r353",
"r354",
"r355",
"r356",
"r357",
"r358",
"r359",
"r360",
"r361",
"r362",
"r363",
"r364",
"r365",
"r366",
"r367",
"r368",
"r369",
"r370",
"r371",
"r372",
"r374",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r383",
"r384",
"r385",
"r386",
"r387",
"r388",
"r389",
"r390",
"r391",
"r392",
"r393",
"r394",
"r396",
"r397",
"r398",
"r399"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
"label": "Retirement Plan Type [Domain]",
"terseLabel": "Retirement Plan Type [Domain]"
}
}
},
"localname": "RetirementPlanTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": {
"auth_ref": [
"r450",
"r453"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606.",
"label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer",
"terseLabel": "Collaboration revenues",
"verboseLabel": "International - AbbVie's share of profits (included in net revenues)"
}
}
},
"localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RevenueFromContractWithCustomerAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Revenue from Contract with Customer [Abstract]",
"terseLabel": "Revenue from Contract with Customer [Abstract]"
}
}
},
"localname": "RevenueFromContractWithCustomerAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
"auth_ref": [
"r172",
"r173",
"r179",
"r183",
"r184",
"r190",
"r191",
"r194",
"r311",
"r312",
"r581"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
"label": "Revenue from Contract with Customer, Excluding Assessed Tax",
"terseLabel": "Net revenues"
}
}
},
"localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_Revenues": {
"auth_ref": [
"r78",
"r113",
"r172",
"r173",
"r179",
"r183",
"r184",
"r190",
"r191",
"r194",
"r203",
"r261",
"r262",
"r263",
"r265",
"r266",
"r267",
"r268",
"r269",
"r270",
"r271",
"r541",
"r604"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": 2.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
"label": "Revenues",
"terseLabel": "Net revenues",
"verboseLabel": "Total net revenues"
}
}
},
"localname": "Revenues",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
"http://www.abbvie.com/role/SegmentInformationDisaggregationofRevenueDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SalesRevenueNetMember": {
"auth_ref": [
"r165",
"r194"
],
"lang": {
"en-us": {
"role": {
"documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
"label": "Revenue Benchmark [Member]",
"terseLabel": "Total revenues"
}
}
},
"localname": "SalesRevenueNetMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresConcentrationsofRiskDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
"auth_ref": [
"r65",
"r556",
"r558"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
"label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
"terseLabel": "Summary of changes in balances of each component of accumulated other comprehensive loss"
}
}
},
"localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
"auth_ref": [
"r493"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.",
"label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
"terseLabel": "Schedule of pre-tax amounts of derivatives designated as cash flow hedges recognized in other comprehensive income (loss)"
}
}
},
"localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
"auth_ref": [
"r454"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
"terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
}
}
},
"localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/CollaborationsTables",
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
"auth_ref": [
"r454"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
"terseLabel": "Schedule of profit and cost sharing relationship"
}
}
},
"localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CollaborationsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
"auth_ref": [
"r373",
"r374",
"r375",
"r376",
"r387"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
"label": "Schedule of Defined Benefit Plans Disclosures [Table]",
"terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
}
}
},
"localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/PostEmploymentBenefitsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
"auth_ref": [
"r484",
"r496",
"r503"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
"label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
"terseLabel": "Summary of pre-tax amounts and location of derivatives recognized in the condensed consolidated statements of earnings"
}
}
},
"localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
"auth_ref": [
"r490"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
"label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
"terseLabel": "Summary of amounts and location of derivatives on the condensed consolidated balance sheets"
}
}
},
"localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfDividendsPayableTextBlock": {
"auth_ref": [
"r109"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of all or some of the information related to dividends declared, but not paid, as of the financial reporting date.",
"label": "Schedule of Dividends Payable [Table Text Block]",
"terseLabel": "Summary of quarterly cash dividends"
}
}
},
"localname": "ScheduleOfDividendsPayableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
"auth_ref": [
"r151"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
"label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
"terseLabel": "Schedule of basic and diluted earnings per share, impact of two-class method"
}
}
},
"localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EarningsPerShareTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
"auth_ref": [
"r402",
"r410",
"r419"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
"label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
"terseLabel": "Summary of share-based compensation expense"
}
}
},
"localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
"auth_ref": [
"r518",
"r519"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
"label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
"terseLabel": "Summary of bases used to measure assets and liabilities carried at fair value on a recurring basis"
}
}
},
"localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
"auth_ref": [
"r216",
"r220",
"r582"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
"label": "Schedule of Finite-Lived Intangible Assets [Table]",
"terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
}
}
},
"localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsIntangibleAssetsNetDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
"auth_ref": [
"r216",
"r220"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
"label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
"terseLabel": "Summary of definite-lived intangible assets"
}
}
},
"localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfGoodwillTextBlock": {
"auth_ref": [
"r212",
"r213"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
"label": "Schedule of Goodwill [Table Text Block]",
"terseLabel": "Summary of changes in the carrying amount of goodwill"
}
}
},
"localname": "ScheduleOfGoodwillTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
"auth_ref": [
"r223",
"r225"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
"label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
"terseLabel": "Summary of indefinite-lived intangible assets"
}
}
},
"localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/GoodwillandIntangibleAssetsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
"auth_ref": [
"r9",
"r30",
"r31",
"r32"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
"label": "Schedule of Inventory, Current [Table Text Block]",
"terseLabel": "Schedule of inventories"
}
}
},
"localname": "ScheduleOfInventoryCurrentTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SupplementalFinancialInformationTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
"auth_ref": [
"r358"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
"label": "Schedule of Net Benefit Costs [Table Text Block]",
"terseLabel": "Summary of net periodic benefit costs relating to the company's defined benefit and other post-employment plans"
}
}
},
"localname": "ScheduleOfNetBenefitCostsTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/PostEmploymentBenefitsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
"auth_ref": [
"r498"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
"label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
"terseLabel": "Schedule of pre-tax amounts of derivatives designated as net investment hedges recognized in other comprehensive income (loss)"
}
}
},
"localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
"auth_ref": [
"r233",
"r234",
"r235",
"r236",
"r242",
"r243",
"r244"
],
"lang": {
"en-us": {
"role": {
"documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
"label": "Schedule of Restructuring and Related Costs [Table]",
"terseLabel": "Schedule of Restructuring and Related Costs [Table]"
}
}
},
"localname": "ScheduleOfRestructuringAndRelatedCostsTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
"http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
"auth_ref": [
"r238",
"r239",
"r241"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
"label": "Restructuring and Related Costs [Table Text Block]",
"terseLabel": "Summary of charges associated with integration plan"
}
}
},
"localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
"auth_ref": [
"r234",
"r243"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
"label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
"terseLabel": "Summary of cash activity in the restructuring reserve"
}
}
},
"localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
"auth_ref": [
"r404",
"r413"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about share-based payment arrangement.",
"label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
"terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
}
}
},
"localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
"http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
"http://www.abbvie.com/role/EquityStockOptionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SegmentReportingAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Segment Reporting [Abstract]",
"terseLabel": "Segment Reporting [Abstract]"
}
}
},
"localname": "SegmentReportingAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_SegmentReportingDisclosureTextBlock": {
"auth_ref": [
"r168",
"r170",
"r171",
"r177",
"r178",
"r182",
"r186",
"r187",
"r188",
"r189",
"r190",
"r193",
"r194",
"r195"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
"label": "Segment Reporting Disclosure [Text Block]",
"terseLabel": "Segment Information"
}
}
},
"localname": "SegmentReportingDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/SegmentInformation"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SellingGeneralAndAdministrativeExpense": {
"auth_ref": [
"r88"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited": {
"order": 4.0,
"parentTag": "us-gaap_CostsAndExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
"label": "Selling, General and Administrative Expense",
"terseLabel": "Selling, general and administrative"
}
}
},
"localname": "SellingGeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
"label": "Selling, General and Administrative Expenses [Member]",
"terseLabel": "Selling, general and administrative"
}
}
},
"localname": "SellingGeneralAndAdministrativeExpensesMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails",
"http://www.abbvie.com/role/LegalProceedingsandContingenciesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SeniorNotesMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
"label": "Senior Notes [Member]",
"terseLabel": "Senior notes"
}
}
},
"localname": "SeniorNotesMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensation": {
"auth_ref": [
"r105"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
"order": 12.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncash expense for share-based payment arrangement.",
"label": "Share-based Payment Arrangement, Noncash Expense",
"terseLabel": "Stock-based compensation"
}
}
},
"localname": "ShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
"auth_ref": [
"r407"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
"terseLabel": "Shares granted (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r406"
],
"lang": {
"en-us": {
"role": {
"documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
"terseLabel": "Fair market value of awards vested (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
"terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
"http://www.abbvie.com/role/EquityStockBasedCompensationDetails",
"http://www.abbvie.com/role/EquityStockOptionsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Gross number of share options (or share units) granted during the period.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
"terseLabel": "Stock options granted (in shares)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockOptionsDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"auth_ref": [
"r408"
],
"lang": {
"en-us": {
"role": {
"documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
"label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
"terseLabel": "Weighted-average grant-date fair value of the stock options granted (in dollars per share)"
}
}
},
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockOptionsDetails"
],
"xbrltype": "perShareItemType"
},
"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
"auth_ref": [
"r401",
"r405"
],
"lang": {
"en-us": {
"role": {
"documentation": "Award under share-based payment arrangement.",
"label": "Award Type [Domain]",
"terseLabel": "Award Type [Domain]"
}
}
},
"localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityRSUsandPerformanceSharesDetails",
"http://www.abbvie.com/role/EquityStockOptionsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareRepurchaseProgramAxis": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by share repurchase program.",
"label": "Share Repurchase Program [Axis]",
"terseLabel": "Share Repurchase Program [Axis]"
}
}
},
"localname": "ShareRepurchaseProgramAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_ShareRepurchaseProgramDomain": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the share repurchase program.",
"label": "Share Repurchase Program [Domain]",
"terseLabel": "Share Repurchase Program [Domain]"
}
}
},
"localname": "ShareRepurchaseProgramDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SharesOutstanding": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
"label": "Shares, Outstanding",
"periodEndLabel": "Ending balance (in shares)",
"periodStartLabel": "Beginning balance (in shares)"
}
}
},
"localname": "SharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShortTermBorrowings": {
"auth_ref": [
"r12",
"r568",
"r587",
"r610"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
"label": "Short-term Debt",
"terseLabel": "Short-term borrowings"
}
}
},
"localname": "ShortTermBorrowings",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShortTermInvestments": {
"auth_ref": [
"r14",
"r591",
"r592",
"r608"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
"label": "Short-term Investments",
"terseLabel": "Short-term investments"
}
}
},
"localname": "ShortTermInvestments",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShorttermDebtFairValue": {
"auth_ref": [
],
"calculation": {
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails": {
"order": 3.0,
"parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.",
"label": "Short-term Debt, Fair Value",
"terseLabel": "Short-term borrowings"
}
}
},
"localname": "ShorttermDebtFairValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresBasesUsedToMeasureTheApproximateFairValuesOfFinancialInstrumentsDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StatementClassOfStockAxis": {
"auth_ref": [
"r17",
"r18",
"r19",
"r111",
"r113",
"r136",
"r140",
"r145",
"r149",
"r151",
"r159",
"r160",
"r161",
"r203",
"r261",
"r265",
"r266",
"r267",
"r270",
"r271",
"r295",
"r296",
"r299",
"r300",
"r301",
"r541",
"r673"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by the different classes of stock of the entity.",
"label": "Class of Stock [Axis]",
"terseLabel": "Class of Stock [Axis]"
}
}
},
"localname": "StatementClassOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/DocumentandEntityInformation"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r0",
"r46",
"r73",
"r74",
"r75",
"r120",
"r121",
"r122",
"r124",
"r130",
"r132",
"r158",
"r204",
"r301",
"r306",
"r415",
"r416",
"r417",
"r431",
"r432",
"r514",
"r551",
"r552",
"r553",
"r554",
"r555",
"r558",
"r633",
"r634",
"r635",
"r675"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by component of equity.",
"label": "Equity Components [Axis]",
"terseLabel": "Equity Components [Axis]"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails",
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Statement [Line Items]",
"terseLabel": "Statement"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement of Cash Flows [Abstract]",
"terseLabel": "Statement of Cash Flows [Abstract]"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement of Financial Position [Abstract]",
"terseLabel": "Statement of Financial Position [Abstract]"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement of Comprehensive Income [Abstract]",
"terseLabel": "Statement of Comprehensive Income [Abstract]"
}
}
},
"localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Statement of Stockholders' Equity [Abstract]",
"terseLabel": "Statement of Stockholders' Equity [Abstract]"
}
}
},
"localname": "StatementOfStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
"r120",
"r121",
"r122",
"r158",
"r581"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]",
"terseLabel": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
"auth_ref": [
"r18",
"r19",
"r301",
"r306"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
"label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
"terseLabel": "Stock-based compensation plans and other (in shares)"
}
}
},
"localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
"auth_ref": [
"r18",
"r19",
"r306",
"r403",
"r408"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
"label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
"terseLabel": "Stock-based compensation plans and other"
}
}
},
"localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
"auth_ref": [
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount remaining of a stock repurchase plan authorized.",
"label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
"terseLabel": "Remaining share repurchase authorization amount"
}
}
},
"localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r19",
"r24",
"r25",
"r113",
"r198",
"r203",
"r541",
"r568"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
"label": "Stockholders' Equity Attributable to Parent",
"totalLabel": "Total stockholders' equity"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Stockholders' Equity Attributable to Parent [Abstract]",
"terseLabel": "Stockholders' equity"
}
}
},
"localname": "StockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
"auth_ref": [
"r0",
"r1",
"r74",
"r113",
"r120",
"r121",
"r122",
"r124",
"r130",
"r203",
"r204",
"r306",
"r415",
"r416",
"r417",
"r431",
"r432",
"r456",
"r457",
"r470",
"r514",
"r541",
"r551",
"r552",
"r558",
"r634",
"r635",
"r675"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 6.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
"label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
"periodEndLabel": "Ending balance",
"periodStartLabel": "Beginning balance",
"totalLabel": "Total equity"
}
}
},
"localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets",
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
"http://www.abbvie.com/role/EquityAccumulatedOtherComprehensiveLossDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityNoteAbstract": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"label": "Stockholders' Equity Note [Abstract]",
"terseLabel": "Stockholders' Equity Note [Abstract]"
}
}
},
"localname": "StockholdersEquityNoteAbstract",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventMember": {
"auth_ref": [
"r559",
"r569"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event [Member]",
"terseLabel": "Subsequent event"
}
}
},
"localname": "SubsequentEventMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SubsequentEventTypeAxis": {
"auth_ref": [
"r559",
"r569"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event Type [Axis]",
"terseLabel": "Subsequent Event Type [Axis]"
}
}
},
"localname": "SubsequentEventTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventTypeDomain": {
"auth_ref": [
"r559",
"r569"
],
"lang": {
"en-us": {
"role": {
"documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event Type [Domain]",
"terseLabel": "Subsequent Event Type [Domain]"
}
}
},
"localname": "SubsequentEventTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresDebtandCreditFacilitiesDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_TreasuryLockMember": {
"auth_ref": [
],
"lang": {
"en-us": {
"role": {
"documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period.",
"label": "Treasury Lock [Member]",
"terseLabel": "Treasury rate lock agreements"
}
}
},
"localname": "TreasuryLockMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/EquityAmountsReclassifiedOutOfAccumulatedOtherComprehensiveLossDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresAmountOfGainLossRecognizedForDerivativeInstrumentsDetails",
"http://www.abbvie.com/role/FinancialInstrumentsandFairValueMeasuresFinancialInstrumentsDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_TreasuryStockMember": {
"auth_ref": [
"r45",
"r307"
],
"lang": {
"en-us": {
"role": {
"documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
"label": "Treasury Stock [Member]",
"terseLabel": "Treasury stock"
}
}
},
"localname": "TreasuryStockMember",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_TreasuryStockShares": {
"auth_ref": [
"r45",
"r307"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
"label": "Treasury Stock, Shares",
"terseLabel": "Common stock held in treasury, at cost (in shares)"
}
}
},
"localname": "TreasuryStockShares",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_TreasuryStockSharesAcquired": {
"auth_ref": [
"r19",
"r301",
"r306"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
"label": "Treasury Stock, Shares, Acquired",
"negatedTerseLabel": "Purchases of treasury stock (in shares)",
"terseLabel": "Shares repurchased (in shares)"
}
}
},
"localname": "TreasuryStockSharesAcquired",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
"http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_TreasuryStockValue": {
"auth_ref": [
"r45",
"r307",
"r310"
],
"calculation": {
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
"label": "Treasury Stock, Value",
"negatedLabel": "Common stock held in treasury, at cost, 44,595,448 shares as of June 30, 2022 and 34,857,597 as of December 31, 2021"
}
}
},
"localname": "TreasuryStockValue",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_TreasuryStockValueAcquiredCostMethod": {
"auth_ref": [
"r301",
"r306",
"r307"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
"label": "Treasury Stock, Value, Acquired, Cost Method",
"negatedTerseLabel": "Purchases of treasury stock",
"terseLabel": "Payment for shares repurchased"
}
}
},
"localname": "TreasuryStockValueAcquiredCostMethod",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEquityUnaudited",
"http://www.abbvie.com/role/EquityStockRepurchaseProgramDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_TypeOfArrangementAxis": {
"auth_ref": [
"r454"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
"label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
"terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
}
}
},
"localname": "TypeOfArrangementAxis",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CollaborationsDetails",
"http://www.abbvie.com/role/LicensingAcquisitionsandOtherArrangementsDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_TypeOfRestructuringDomain": {
"auth_ref": [
"r233",
"r234",
"r242",
"r243"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identification of the types of restructuring costs.",
"label": "Type of Restructuring [Domain]",
"terseLabel": "Type of Restructuring [Domain]"
}
}
},
"localname": "TypeOfRestructuringDomain",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/IntegrationandRestructuringPlansDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"auth_ref": [
"r135",
"r151"
],
"calculation": {
"http://www.abbvie.com/role/EarningsPerShareDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"lang": {
"en-us": {
"role": {
"documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
"label": "Weighted Average Number of Shares Outstanding, Diluted",
"terseLabel": "Weighted-average diluted shares outstanding (in shares)",
"totalLabel": "Weighted-average diluted shares outstanding (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
"http://www.abbvie.com/role/EarningsPerShareDetails"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
"auth_ref": [
"r133",
"r151"
],
"calculation": {
"http://www.abbvie.com/role/EarningsPerShareDetails": {
"order": 1.0,
"parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
"label": "Weighted Average Number of Shares Outstanding, Basic",
"terseLabel": "Weighted-average basic shares outstanding (in shares)",
"verboseLabel": "Weighted-average basic shares outstanding (in shares)"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingBasic",
"nsuri": "http://fasb.org/us-gaap/2021-01-31",
"presentation": [
"http://www.abbvie.com/role/CondensedConsolidatedStatementsofEarningsUnaudited",
"http://www.abbvie.com/role/EarningsPerShareDetails"
],
"xbrltype": "sharesItemType"
}
},
"unitCount": 14
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "105",
"URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "105",
"URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(13))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r100": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
},
"r101": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(14))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
},
"r111": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(d))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(f))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h)(2))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(m)(1)(iii))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(m)(2)(ii))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-04(a))",
"Topic": "235",
"URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(19)(a))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(19))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
},
"r138": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "28A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(2))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
},
"r141": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)(1)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "55",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
},
"r146": {
"Name": "Accounting Standards Codification",
"Paragraph": "60",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2740-109256"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
},
"r148": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "52",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
},
"r157": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "260",
"URI": "http://asc.fasb.org/topic&trid=2144383"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(22))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "272",
"URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "275",
"URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "26",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r185": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r188": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "34",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "42",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
},
"r195": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "280",
"URI": "http://asc.fasb.org/topic&trid=2134510"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
},
"r2": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "205",
"URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(3))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(aa)",
"Topic": "320",
"URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "321",
"URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "326",
"URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.BB)",
"Topic": "330",
"URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r210": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "((a)(1),(b))",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(1)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(2)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(b),(d)",
"Topic": "350",
"URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
},
"r226": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "350",
"URI": "http://asc.fasb.org/topic&trid=2144416"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(4))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "360",
"URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(1)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r236": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r237": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r238": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 5.P.3)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r240": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 5.P.4)",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(b)(1))",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(b)(2))",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r244": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(d))",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r245": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.P.4(e))",
"Topic": "420",
"URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
},
"r246": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "420",
"URI": "http://asc.fasb.org/topic&trid=2175745"
},
"r247": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
},
"r251": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
},
"r255": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
},
"r256": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "450",
"URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
},
"r257": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "450",
"URI": "http://asc.fasb.org/topic&trid=2127136"
},
"r258": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "460",
"URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
},
"r259": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "460",
"URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r264": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(5))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
},
"r267": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(i))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(1))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(5))",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
},
"r272": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r275": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r278": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
},
"r279": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(3))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r280": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r281": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
},
"r282": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r283": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
},
"r285": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r286": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r287": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r288": {
"Name": "Accounting Standards Codification",
"Paragraph": "1F",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
},
"r289": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a)(4))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r290": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
},
"r291": {
"Name": "Accounting Standards Codification",
"Paragraph": "69B",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
},
"r292": {
"Name": "Accounting Standards Codification",
"Paragraph": "69C",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
},
"r293": {
"Name": "Accounting Standards Codification",
"Paragraph": "69E",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
},
"r294": {
"Name": "Accounting Standards Codification",
"Paragraph": "69F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
},
"r295": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
},
"r296": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
},
"r297": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
},
"r298": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
},
"r299": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
},
"r3": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "205",
"URI": "http://asc.fasb.org/topic&trid=2122149"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(a))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r300": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
},
"r301": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
},
"r302": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
},
"r303": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
},
"r304": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
},
"r305": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
},
"r306": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
},
"r307": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
},
"r308": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
},
"r309": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(b))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r310": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "505",
"URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
},
"r311": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
},
"r312": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
},
"r313": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
},
"r314": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
},
"r315": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
},
"r316": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
},
"r317": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
},
"r318": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
},
"r319": {
"Name": "Accounting Standards Codification",
"Paragraph": "91",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "606",
"URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(6)(c))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r320": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "15",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "712",
"URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
},
"r321": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "15",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "712",
"URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
},
"r322": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "712",
"URI": "http://asc.fasb.org/extlink&oid=6410195&loc=d3e80090-111668"
},
"r323": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "712",
"URI": "http://asc.fasb.org/topic&trid=2197446"
},
"r324": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919"
},
"r325": {
"Name": "Accounting Standards Codification",
"Paragraph": "3A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919"
},
"r326": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r327": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(1)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r328": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(10)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r329": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(2)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.1)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r330": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(3)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r331": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(4)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r332": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(5)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r333": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(6)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r334": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(7)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r335": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(8)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r336": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(9)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r337": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r338": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r339": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.12)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r340": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r341": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(4)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r342": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(5)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r343": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(6)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r344": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(7)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r345": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(8)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r346": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r347": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(i)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r348": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(ii)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r349": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(01)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.13)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r350": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r351": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(A)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r352": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(B)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r353": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(C)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r354": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(03)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r355": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r356": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(f)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r357": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r358": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r359": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)(1)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.14)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r360": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)(2)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r361": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)(3)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r362": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)(4)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r363": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)(5)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r364": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)(6)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r365": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)(7)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r366": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(i)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r367": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(j)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r368": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(k)(1)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r369": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(k)(3)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.17)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r370": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(k)(4)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r371": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(n)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r372": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(q)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r373": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
},
"r374": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
},
"r375": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
},
"r376": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
},
"r377": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r378": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(1)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r379": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(2)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19,20)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r380": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(3)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r381": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(4)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r382": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(5)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r383": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(6)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r384": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(7)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r385": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
},
"r386": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
},
"r387": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
},
"r388": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921"
},
"r389": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "70",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r390": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "80",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
},
"r391": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(a)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
},
"r392": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(b)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
},
"r393": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(c)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
},
"r394": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
},
"r395": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(d)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
},
"r396": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(a)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
},
"r397": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(b)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
},
"r398": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(c)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
},
"r399": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "80",
"Subparagraph": "(b)",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r400": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "80",
"Topic": "715",
"URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
},
"r401": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
},
"r402": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
},
"r403": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
},
"r404": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
},
"r405": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a),(g)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r406": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(i)-(ii)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r407": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)(iii)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r408": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r409": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(a)(1))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r410": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r411": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)(1)(i)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r412": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(i)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r413": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
},
"r414": {
"Name": "Accounting Standards Codification",
"Paragraph": "2A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
},
"r415": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r416": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r417": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r418": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(g)(2)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
},
"r419": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 14.F)",
"Topic": "718",
"URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r420": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "718",
"URI": "http://asc.fasb.org/topic&trid=2228938"
},
"r421": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "730",
"URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
},
"r422": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
},
"r423": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
},
"r424": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
},
"r425": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
},
"r426": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
},
"r427": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
},
"r428": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
},
"r429": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.24)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r430": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
},
"r431": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
},
"r432": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
},
"r433": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r434": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 6.I.7)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r435": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.7)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r436": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.Fact.1)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r437": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.Fact.2)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r438": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.Fact.4)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
},
"r439": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.C)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.25)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r440": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
},
"r441": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "270",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
},
"r442": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
},
"r443": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "740",
"URI": "http://asc.fasb.org/topic&trid=2144680"
},
"r444": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
},
"r445": {
"Name": "Accounting Standards Codification",
"Paragraph": "38",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
},
"r446": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "30",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
},
"r447": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
},
"r448": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(c)(1)",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
},
"r449": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)(1)",
"Topic": "805",
"URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29,30)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r450": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "808",
"URI": "http://asc.fasb.org/extlink&oid=123385629&loc=SL5834089-161433"
},
"r451": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "808",
"URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
},
"r452": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "808",
"URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
},
"r453": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "808",
"URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
},
"r454": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "808",
"URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
},
"r455": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "808",
"URI": "http://asc.fasb.org/topic&trid=5833765"
},
"r456": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
},
"r457": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
},
"r458": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
},
"r459": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r460": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
},
"r461": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r462": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
},
"r463": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r464": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(2)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r465": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r466": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(3)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r467": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c),(3)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
},
"r468": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r469": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.31)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r470": {
"Name": "Accounting Standards Codification",
"Paragraph": "4I",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
},
"r471": {
"Name": "Accounting Standards Codification",
"Paragraph": "4J",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
},
"r472": {
"Name": "Accounting Standards Codification",
"Paragraph": "4K",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "810",
"URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
},
"r473": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "810",
"URI": "http://asc.fasb.org/topic&trid=2197479"
},
"r474": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
},
"r475": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
},
"r476": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
},
"r477": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
},
"r478": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)(i)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
},
"r479": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)(ii)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.6(a))",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r480": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)(iii)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
},
"r481": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
},
"r482": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
},
"r483": {
"Name": "Accounting Standards Codification",
"Paragraph": "4A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
},
"r484": {
"Name": "Accounting Standards Codification",
"Paragraph": "4A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
},
"r485": {
"Name": "Accounting Standards Codification",
"Paragraph": "4A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(1)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
},
"r486": {
"Name": "Accounting Standards Codification",
"Paragraph": "4A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
},
"r487": {
"Name": "Accounting Standards Codification",
"Paragraph": "4B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a),(c)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
},
"r488": {
"Name": "Accounting Standards Codification",
"Paragraph": "4B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
},
"r489": {
"Name": "Accounting Standards Codification",
"Paragraph": "4B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.9)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
},
"r490": {
"Name": "Accounting Standards Codification",
"Paragraph": "4B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
},
"r491": {
"Name": "Accounting Standards Codification",
"Paragraph": "4C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
},
"r492": {
"Name": "Accounting Standards Codification",
"Paragraph": "4C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
},
"r493": {
"Name": "Accounting Standards Codification",
"Paragraph": "4C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
},
"r494": {
"Name": "Accounting Standards Codification",
"Paragraph": "4C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
},
"r495": {
"Name": "Accounting Standards Codification",
"Paragraph": "4C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
},
"r496": {
"Name": "Accounting Standards Codification",
"Paragraph": "4C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
},
"r497": {
"Name": "Accounting Standards Codification",
"Paragraph": "4CCC",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
},
"r498": {
"Name": "Accounting Standards Codification",
"Paragraph": "4CCC",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
},
"r499": {
"Name": "Accounting Standards Codification",
"Paragraph": "4D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(1)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
},
"r500": {
"Name": "Accounting Standards Codification",
"Paragraph": "4D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)(2)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
},
"r501": {
"Name": "Accounting Standards Codification",
"Paragraph": "4D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
},
"r502": {
"Name": "Accounting Standards Codification",
"Paragraph": "4D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
},
"r503": {
"Name": "Accounting Standards Codification",
"Paragraph": "4E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
},
"r504": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
},
"r505": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
},
"r506": {
"Name": "Accounting Standards Codification",
"Paragraph": "182",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
},
"r507": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977"
},
"r508": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "25",
"Subparagraph": "(a)(2)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
},
"r509": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "25",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
},
"r510": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
},
"r511": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
},
"r512": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
},
"r513": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
},
"r514": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(3)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
},
"r515": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(4)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
},
"r516": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
},
"r517": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "815",
"URI": "http://asc.fasb.org/topic&trid=2229140"
},
"r518": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r519": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
},
"r520": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r521": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r522": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(1)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r523": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(2)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r524": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r525": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r526": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(2)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r527": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(3)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r528": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
},
"r529": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
},
"r530": {
"Name": "Accounting Standards Codification",
"Paragraph": "6A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
},
"r531": {
"Name": "Accounting Standards Codification",
"Paragraph": "6A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
},
"r532": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "820",
"URI": "http://asc.fasb.org/topic&trid=2155941"
},
"r533": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
},
"r534": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
},
"r535": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
},
"r536": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
},
"r537": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
},
"r538": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
},
"r539": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
},
"r540": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
},
"r541": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
},
"r542": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
},
"r543": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28129-110885"
},
"r544": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
},
"r545": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892"
},
"r546": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
},
"r547": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
},
"r548": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
},
"r549": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
},
"r550": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
},
"r551": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
},
"r552": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r553": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r554": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r555": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r556": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
},
"r557": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
},
"r558": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
},
"r559": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a),(b),(c)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
},
"r560": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
},
"r561": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
},
"r562": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
},
"r563": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
},
"r564": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
},
"r565": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "30",
"Topic": "835",
"URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
},
"r566": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "852",
"URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r567": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "852",
"URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
},
"r568": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "852",
"URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
},
"r569": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "855",
"URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a-c)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
},
"r570": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r571": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r572": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r573": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r574": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r575": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
},
"r576": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r577": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r578": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
},
"r579": {
"Name": "Accounting Standards Codification",
"Paragraph": "4D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)(2)",
"Topic": "860",
"URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
},
"r580": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "910",
"URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
},
"r581": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
},
"r582": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "926",
"URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
},
"r583": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "340",
"Topic": "928",
"URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
},
"r584": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "20",
"Topic": "940",
"URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
},
"r585": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(10)(1))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r586": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r587": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(13))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r588": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(16))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r589": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(22))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(i),(j),(k)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
},
"r590": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r591": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(4))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r592": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(5))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r593": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(6))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r594": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.13,16)",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r595": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.17)",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
},
"r596": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(15))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r597": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(22))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r598": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(23))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r599": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(24))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(i-k)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
},
"r600": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(25))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r601": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(26))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r602": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(27))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r603": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04.9)",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
},
"r604": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "235",
"Subparagraph": "(SX 210.9-05(b)(2))",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
},
"r605": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "360",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
},
"r606": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "470",
"Topic": "942",
"URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
},
"r607": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(16))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r608": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(1)(g))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r609": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "10A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
},
"r610": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r611": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(16))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r612": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r613": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r614": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(24))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r615": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r616": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(8))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r617": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.(a),19)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r618": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03.16)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
},
"r619": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(18))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r62": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
},
"r620": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(19))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r621": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(20))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r622": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(21))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r623": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(22))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r624": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(23))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r625": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(8))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r626": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(9))",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
},
"r627": {
"Name": "Accounting Standards Codification",
"Paragraph": "4H",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
},
"r628": {
"Name": "Accounting Standards Codification",
"Paragraph": "7A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "40",
"Subparagraph": "(d)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
},
"r629": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(a)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
},
"r630": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(b)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
},
"r631": {
"Name": "Accounting Standards Codification",
"Paragraph": "13H",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Subparagraph": "(c)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
},
"r632": {
"Name": "Accounting Standards Codification",
"Paragraph": "29F",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "40",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
},
"r633": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r634": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r635": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r636": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r637": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(ii)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r638": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
},
"r639": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "825",
"Topic": "944",
"URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
},
"r640": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
},
"r641": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
},
"r642": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
},
"r643": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
},
"r644": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
},
"r645": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
},
"r646": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
},
"r647": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
},
"r648": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
},
"r649": {
"Name": "Accounting Standards Codification",
"Paragraph": "5D",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "14A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
},
"r650": {
"Name": "Accounting Standards Codification",
"Paragraph": "5D",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
},
"r651": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-15(Column A))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
},
"r652": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-15(Column B))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
},
"r653": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-15(Column C))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
},
"r654": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-15(Column D))",
"Topic": "946",
"URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
},
"r655": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "310",
"Subparagraph": "(SX 210.12-29(Footnote 4))",
"Topic": "948",
"URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
},
"r656": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Topic": "954",
"URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
},
"r657": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column B))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r658": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column C))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r659": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column D))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "17A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL34724391-108580"
},
"r660": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column E))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r661": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column F))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r662": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column G))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r663": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column H))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r664": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Column I))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r665": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Footnote 2))",
"Topic": "970",
"URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
},
"r666": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(c)",
"Topic": "976",
"URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
},
"r667": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "310",
"Subparagraph": "(b)",
"Topic": "978",
"URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
},
"r668": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b"
},
"r669": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
},
"r670": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "308",
"Subsection": "a"
},
"r671": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1"
},
"r672": {
"Name": "Regulation 12B",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2"
},
"r673": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(a)",
"Publisher": "SEC",
"Section": "1402"
},
"r674": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405"
},
"r675": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)(3)(iii)(03)",
"Topic": "848"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
},
"r75": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
},
"r76": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(210.5-03(11))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(1))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r79": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(10))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
},
"r80": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(20))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r81": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(21))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(22))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(23))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(24))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(25))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.2(a),(d))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r89": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.7(b))",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "210",
"URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.9)",
"Topic": "220",
"URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a),(b)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "230",
"URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
}
},
"version": "2.1"
} |
